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RR   - Reduced RNase A 
SAMC   - S-allylmercaptocysteine 
± SD   - Standard Deviation 
SDS   - Sodium Dodecyl Sulfate 
SLS   - Sodium Lauryl Sulfate 
S-MMTS  - S-methylmethane Thiosulfonate 
THF   - Tetrahydrafuran 
TLC   - Thin Layer Chromatography 
UPR   - Unfolded Protein Response 
V   - Volts 
VCR   - Vincristine 
VLB   - Vinblastine 




Table of contents: 
Declaration           i 
Acknowledgments          ii 
List of Abbreviations         iii 
Table of contents          vii 
Abstract           1 
Chapter 1: Introduction         2 
1.1. Cancer           2 
1.1.1. Oesophageal cancer         3 
1.2. Cancer treatments         4 
1.3. Anti-cancer compounds from natural sources     5 
1.4. Garlic-derived anti-cancer agents       7 
1.4.1. Chemopreventative properties of garlic OSC      8 
1.4.2. Structure-activity insights into the in vitro anti-cancer activity of garlic OSC 9 
1.4.3. In vivo anti-cancer activity of OSC       10 
1.4.4. Structure-activity based OSC studies       11 
1.5. The chemical reactivity of the disulfide bond: thermostability and kinetics 15 
1.6. Protein thiolation         18 
1.7. Reactive oxygen species         19 
1.7.1.  Evidence for ROS in the in vitro anti-cancer mechanism of OSC   19 
1.7.2. ROS production mechanism        22 
1.8. Protein disulfide isomerase        23 
1.9. Analogues of garlic-derived OSC       27 
1.10. Hypothesis          30 





Chapter 2: Investigating structure-anti-proliferation relationships of DADS and 
thiosulfonate compounds in WHCO1 oesophageal cancer cells    32 
2.1. Introduction          32 
2.2. Results           33 
2.2.1. Cell viability (MTT assay)        33 
2.2.2. Predictive pKa-values of OSC leaving groups     36 
2.3. Discussion          39 
 
Chapter 3: Investigating the in vitro anti-cancer mechanism of t-PMB and 200 in 
WHCO1 oesophageal cancer cells        46 
3.1. Introduction          46 
3.2. Results           47 
3.2.1. Proliferation assay (BrdU assay)       47 
3.2.2. Cytotoxicity of t-PMB and 200 in tumour and non-tumour cell-lines  47 
3.2.3.  Morphology          49 
3.2.4. Cell-cycle analysis         51 
3.2.5.  Apoptosis (histone dissociation)       53 
3.2.6.  ROS production         55 
3.2.7. ROS inhibition         57 
3.2.8.  Reaction between NAC and t-PMB       61 
3.3. Discussion          64 
 
Chapter 4: In vivo anti-cancer activity of t-PMB and 200 (UCT AEC protocol number 
012/003)           68 
4.1. Introduction          68 
4.2. Results           69 
4.2.1. Nude mice with A375 xenografts treated intraperitonealy with 200   69 
4.2.2. Nude mice with WHCO1 xenografts treated intraperitonealy with 200  72 
4.2.3. Nude mice with A375 xenografts treated intraperitonealy with t-PMB  75 




Chapter 5: Investigating protein disulfide isomerase as a potential drug target for  
OSC            81 
5.1. Introduction          81 
5.2. Results           82 
5.2.1. Immunofluorescence         82 
5.2.2. PDI enzyme assay         83 
5.3. Discussion          87 
 
Chapter 6: General discussion        89 
 
Chapter 7: Conclusion         97 
 
Chapter 8: Materials and methods        99 
8.1. Determining compound purity and stability      99 
8.1.1. Thin layer chromatography (TLC)       99 
8.1.2. Nuclear magnetic resonance (NMR)       99 
8.2. Toxicity studies          99 
8.2.1. Cell lines used in assay        99 
8.2.2. Cell culture media         100 
8.2.3. Cell maintenance         100 
8.2.3.1.  Storage of cells        100 
8.2.3.2.  Thawing         101 
8.2.3.3.  Plating and splitting        101 
8.2.4. Cell count          101 
8.3. Cell morphology          101 
8.4. Cell viability (MTT assay)        102 
8.4.1. Cell culturing          102 
8.5. Cell proliferation assay (BrdU assay)       103 




8.6. Cell-cycle analysis by fluorescence activated cell sorting (FACS) analysis  104 
8.7. Histone dissociation assay        104 
8.7.1. ELISA assay          105 
8.8. ROS assay          105 
8.8.1. Treating with DCFH-DA and OSC       106 
8.8.2. ROS inhibition         106 
8.8.3. NMR on NAC and t-PMB reaction product      107 
8.9. Tumour growth in nude mice        107 
8.9.1. Preparing WHCO1 oesophageal and A375 melanoma cancer cell-lines  107 
8.9.2. Preparing OSC         107 
8.9.3. Pharmacokinetic data on 200        108 
8.10. Protein disulfide isomerase (PDI)       109 
8.10.1. Detection of PDI in various cell-lines      109 
8.10.2. Immunohistochemistry        111 
8.10.2.1.  Cell culturing         111 
8.10.3. PDI enzyme assay         111 
 
References           113 
 








Crushed garlic contains organosulfur compounds (OSC), which are reported to have cancer 
chemotherapeutic properties both in vitro and in vivo. A library of 15 organosulfur analogues 
were obtained as mechanistic probes in WHCO1 oesophageal cancer cells. Structure-activity 
studies showed a positive correlation between the anti-proliferative-IC50 of disulfides and the 
relative stability of their anion leaving groups, as assessed through resonance and quantified 
by predictive pKa-values. 
Compounds t-PMB (IC50 = 15 μM), a thiosulfonate, and 200 (IC50 = 10 μM), a diallyl 
disulfide (DADS) analogue, were selected for further mechanistic evaluation and showed to 
induce both G2/M cell-cycle arrest and apoptosis in WHCO1 cells. Although treatment with 
t-PMB, but not 200, resulted in increased ROS levels, treatment with ROS inhibitors showed 
that ROS production was not important for t-PMB-induced WHCO1 cell-death.  
In vivo studies showed that 30 mg/kg t-PMB daily and 20 mg/kg 200 every second day 
significantly reduced A375 human melanoma tumour growth in nude mice within the first 16 
days only, although t-PMB-treated mice experienced abdominal swelling side effects. Nude 
mice with the WHCO1 oesophageal cancer xenograft treated with 10 mg/kg 200 daily 
showed a significant reduction in tumour size up to 7 days.  
Using immunohistochemistry, we observed co-localisation of DP and protein disulfide 
isomerase (PDI) in KYSE-180 cells, and furthermore found that OSC inhibited PDIs 















Cancer is a heterogenous disease that can form almost anywhere in the body. The disease has 
a complex nature, where a cell or cells require a number of insults before it can progress to a 
state of malignancy. There are several characteristics which mark a cell as one that is 
cancerous; these characteristics have been termed the six hallmarks of cancer by Hanahan et 
al. (2011). The hallmarks provide a logical framework for understanding the disease and 
include: sustained proliferative signalling, evasion of growth suppressors, activation of 
invasion and metastasis, enabled replicative immortality, angiogenesis and resistance to cell 
death (Figure 1.1) (Hanahan et al. 2000; Hanahan & Weinberg 2011). 
 
 
Figure 1.1. The Six Hallmarks of Cancer. The six hallmarks of cancer comprise of altered 
biological properties acquired by the cell during the development of human tumours. These six 
hallmarks include; resistance to cell death, sustained proliferative signalling, evasion of growth 
suppressors , evasion of metastasis, enabled replicative immortality and induction of  angiogenesis 




The prevalence of the disease is determined by both environmental and genetic factors 
affecting an individual (Fearnhead et al. 2002; Zbar et al. 1995), and furthermore, certain 
cancers have been shown to have gender specificity (Van Rensburg et al. 1985; Shaaban et 
al. 2012). In January 2013, the World Health Organisation (WHO) confirmed cancer to be 
the leading cause of human death world-wide (7.6 million deaths) and it is estimated that this 
number will rise to 13.1 million deaths by 2030.  
1.1.1. Oesophageal cancer 
In 2013, the WHO reported oesophageal cancer to be the 9
th
 most commonly diagnosed 
cancer world-wide, and the 7
th
 most lethal cancer. The two main types of oesophageal 
cancers include squamous cell carcinoma and adenocarcinoma. Squamous cell carcinoma 
usually occurs in the middle to upper third part of the oesophagus, and is associated with 
environmental insults such as alcohol intake and tobacco smoking, whilst adenocarcinoma, 
which occurs in the distal oesophagus, is usually associated with gastro-oesophageal reflux 
(Enzinger & Mayer 2003). 
Since 1930, there has been an alarming increase in oesophageal cancer cases in the South 
African population, (Rose & McGlashan 1975; Jemal et al. 2011) (Figure 1.2). Squamous 
cell oesophageal cancer is most prevalent amongst South African black males, and mainly 
occurs in the sixth decade of life (Van Rensburg et al. 1985). Both environmental and genetic 
factors have been associated with squamous cell oesophageal cancer, where genetic profiling 
studies have shown that the deletion of GSTT2B, a polymorphic variant of the glutathione S-
transferase gene, may have a protective effect on the risk of oesophageal squamous cell 
carcinoma in mixed ancestry South African populations (Matejcic et al. 2011). A number of 
environmental factors have been implicated in the increased risk of oesophageal cancer, 
which includes alcohol, tobacco smoking, carcinogenic exposure as well as diet. Previously, 
it was shown that in certain geographical regions where the staple diet includes sorghum, 
cassava, millet, yams, peanuts or a combination of these, the incidence of oesophageal cancer 
was significantly lower than in regions where corn or wheat was consumed (van Rensburg 
1981). Other parts of the world with high incidences of squamous cell oesophageal cancer 
include Northern Iran, Soviet Central Russia, as well as China. Major risk factors for 
squamous cell oesophageal cancer in these areas are not well understood, but are thought to 
include poor nutrient intake as well as the drinking of beverages at high temperatures (Wu et 




1.2. Cancer treatments 
Due to its complex nature and an incomplete understanding of the disease, developing a cure 
for cancer is a great challenge. A number of therapies have been developed thus far which 
include various forms of chemotherapy, radiation, immunotherapy, surgery and combinations 
thereof (Miller et al. 1981). More recent approaches to cancer treatment is a targeted 
approach which includes nano-particles for drug delivery (Brigger et al. 2012; Peer et al. 
2007) as well as those that target specific cell regulatory proteins (Lowe et al. 1994; Semenza 
2003). 
  
Figure 1.2. Aged standardised oesophageal cancer incidence rates by sex and world area, with the 
statistics for South African males and females boxed in red. Source: GLOBOCAN 2008. 
 
Drugs currently used to inhibit oesophageal tumour growth include fluorouracil, the taxanes 
(Paclitaxel, Docetaxel), the natural alkaloid camptothecin from which irinotecan is derived, 
and cisplatin. It has been demonstrated that chemoresistance to 5-fluorouracil and cisplatin in 




(Hamano et al. 2011). Furthermore, increased expression of the Multidrug Resistance Protein 
2 (MRP2) has been shown in the tissue samples of patients resistant to neo-adjuvant 
chemotherapy including; 5-fluorouracil, doxorubicin and cisplatin (Vermorken et al. 2007). 
Combinations of chemotherapy and radiotherapy have also been shown to be effective, but 
side-effects of this treatment is high, particularly regarding cytotoxicity to non-cancer cells 
(Ilson & Kelson 1993). It is clear that new therapies with increased potency and reduced side-
effects are needed.  
1.3. Anti-cancer compounds from natural sources 
Compounds derived from natural sources have been used in traditional medicines for many 
years (Nobili et al. 2009). Epidemiologic studies have shown that an inverse relationship 
exists between the prevalence of many cancer types and the consumption of fresh fruits and 
vegetables (Surh 2003). Furthermore, throughout history plant materials have been used in 
the treatment of many cancer types (Graham et al. 2000), indicating the potential importance 
of natural products as anti-cancer agents. The United States National Cancer institute (NCI) 
therefore initiated an extensive plant collection programme in 1960 in the hopes of finding 
plant materials that display anti-cancer activity, which resulted in the discovery of many 
novel chemotypes including the taxanes and camptothecins. Since then there have been 
numerous additional reports in the literature of the isolation and identification of novel anti-
cancer agents from nature. 
Natural compounds are the source of about 60 %  of all new drugs that have been developed, 
and about 67 % of the drugs used for chemotherapy are natural products thereof (Cragg et al. 
1997). The first natural anti-cancer agents to advance to clinical use were the vinca alkaloids; 
vinblastine (VLB) and vincristine (VCR) (Figure 1.3) isolated from a plant called the 
Madagascar periwinkle (Catharanthus roseus) (Cragg & Newman 2005). Another relatively 
potent anti-cancer agent is Paclitaxel (taxol®) (Figure 1.3) (Kingston et al. 2005), which was 
initially isolated from the bark of the Pacific yew, Taxus brevifolia, and is used in the 
treatment of breast, ovarian and non-small cell lung cancer. A great deal of research has gone 
into understanding the potential of natural compounds as anti-cancer agents. These 
compounds typically combat some of the hallmarks of cancer to induce cell-cycle arrest, 
apoptosis and inhibiting angiogenesis. Examples of such anti-cancer phytochemicals, and/or 



































































Figure 1.3. The natural sources of anti-cancer phytochemicals shown with their respective chemical 
structures. The garlic-derived organosulfur compound, diallyl disulfide (DADS), is boxed in red (Surh 




1.4. Garlic-derived anti-cancer compounds 
Garlic (Allium sativum) has been used as a folk remedy for many centuries, for illnesses 
including heart disease, high blood pressure and cancer (Borek 2006; Ried et al. 2008; 
Reinhart et al. 2008). The active principles of garlic, which were shown to be lipophilic or 
hydrophillic, have previously been identified to be various organosulfur compounds (OSC) 
found in crushed cloves. Whole garlic contains alliin (S-allylcysteine sulfoxide), which is 
converted to allicin in the presence of an enzyme alliinase only when the clove is crushed or 
damaged (Figure 1.4A). Allicin, which is reported to be active as both an antimicrobial 
(Ankri & Mirelman 1999) and antifungal agent (Davis 2005), is unstable and rearranges 
readily to form an array of second generation OSCs, of which the major lipophilic 
components are diallyl sulfide (DAS), diallyl disulfide (DADS), diallyl trisulfide (DATS) and 
E/Z ajoene ((E/Z) 4,5,9-trithiododeca-1,6,11-triene 9 oxide) (Figure 1.4B) (Kaschula et al. 
2011). The hydophillic second generation OSC’s include S-allylmercaptocysteine (SAMC) 
Figure 1.6) and S-allyl cysteine (SAC) (Table 1.4). These second generation molecules as 
well as allicin, are reported to have both chemotherapeutic and chemopreventive properties 















Figure 1.4. The chemical conversion of alliin to allicin by the enzyme alliinase (A) and the chemical 
structures of the secondary organosulfur compounds (B) as rearrangement products of allicin; (i) E/Z 
ajoene, (ii) diallyl sulfide (DAS), (iii) diallyl disulfide (DADS) and (iv) diallyl trisulfide (DATS) are 
presented. The sulfide or polysulfide pharmacophore (encircled in red) is proposed to be the key 








The composition and concentration of the various OSC from garlic differ depending on the 
type of garlic, as well as the preparation and the age of the extract. Allicin, which is found 
only in fresh extracts, is reported to at a concentration of 2.5-3.1 mg.g
-1
 in garlic (Block et al., 
1986; Kalra & Shukla, 2006). The composition and concentration of second generation OSC 
reported for extracts isolated through steam distillation and oil extraction varies, and is 
reported to be 20-240 mg.g
-1
 for DAS, 280-900 mg.g
-1
 for DADS, 40-200 mg.g
-1
 for DATS 
and 130-480 for E/Z ajoene (Lee et al., 2003; Laakso et al. 1989; Kimbaris et al. 2006; 
Naznin et al. 2008). Other OSC, to include the water-soluble S-allyl cysteine and S-
allylmercaptocysteine, are found to be at relatively low concentrations of < 50 μg.g
-1
. 
1.4.1. Chemopreventative properties of garlic OSC 
The inverse relationship between garlic consumption and occurrence of various cancers has 
been well documented over the last few decades, where the first case-control studies showed 
a negative correlation between the consumption of Allium vegetables and the occurrence of 
gastric cancer (You et al. 1989; Buiatti et al. 1989). Since then, additional documentations of 
case control studies were reported for Europe, the United States, South America and China 
(Fleischauer et al. 2001). 
After having observed the inverse relationship between garlic consumption and occurrence of 
various cancers, a number of studies were performed to investigate the chemopreventative 
effects of garlic-derived OSCs. Initial studies by Wattenberg et al. (1989) showed a 90 % 
reduction in N-nitrosodiethylamine-induced forestomach tumor formation when 0.2 mmol 
DADS was administered 48- and 96-hours before N-nitrosodiethylamine. It was also 
observed that 200 mg/kg DADS and S-allyl cysteine administered via gavage 3 hours prior to 
1,2-dimethylhydrazine (DMH) injection significantly inhibited colonic nuclear damage in 
female C57B1/6J mice (Sumiyoshi & Wargovich, 1990). More recent studies have shown 
that the garlic OSCs may induce their chemopreventative effects by modulating the 
concentration of metabolic enzymes. It is well known that many carcinogens require 
metabolic activation by the cytochrome P450 phase I enzymes, and that subsequent 
inactivation occurs through the phase II enzymes including glutathione transferases. The 
mechanism by which the OSC induce their chemopreventative activity has been shown to 
occur through competitive inhibition of the P450-dependent monooxygenases (phase I 




Herman-Antosiewicz et al. 2007), which together not only prevents carcinogenic activation, 
but also increases its eradication. 
1.4.2  Structure-activity insights into the in vitro anti-cancer activity of garlic 
OSC 
OSC from garlic are reported to inhibit the proliferation of cancer cells both in vitro and in 
vivo, and this activity is proposed to be related to the presence of the disulfide or polysulfide 
functional group, encircled in red in Figure 1.4. All the OSCs displayed in Table 1.1 are 
reported to inhibit cancer cell proliferation with IC50-values in the micro molar (μM) range.  
Table 1.1. The IC50’s of the garlic-derived OSC; E/Z ajoene, DATS, DADS and DAS, at inhibiting 
cell proliferation on various cancer cell-lines, where the IC50 is defined as the compound 
concentration required to inhibit the growth of 50 % of the cells. 
Compound Cell-line Cell type IC50 (µM) Reference 
E/Z Ajoene 
BJA-B Burkitt lymphoma 12 Scharfenberg et al., 1990 
HL60 Pyromyeloleukemic cells 5.2 
Li et al., 2002 
KB Nasopharyngeal carcinoma 15.8 
HT-2 Human colon 19 
Taylor et al., 2006 
A549 Human lung 41 
MDA-MB-231 Human mammary 7 
SKBR-3 Human mammary 19 
PANC-1 Human pancreatic 38 
DATS 
HCT-15 Human colon 11.5 
Hosono et al., 2005 
DLD-1 Human colon 13.3 
PC3 Human Prostate 22 Dong Xiao et al., 2005 
PC3 Human Prostate 72 Chen et al., 2012  
H358 Human lung cancer 20 Xiao et al., 2008 
DADS 
COLO205 Human colon 22.47 Yang et al., 2009 
SW-480 Colon cancer 56 Danhua Xiao et al., 2005 
HL-60 Human leukaemia 25 Kwon et al., 2002 
PC3 Human prostate 35 Dong Xiao et al., 2005 
PC3 Human prostate 40 Arunkumar et al., 2006 
DAS 
SW-480 Colon cancer inactive Danhua Xiao et al., 2005 





The in vitro anti-cancer mechanism of garlic OSC has been investigated, and although the 
mechanism is not empirically known, ROS production, cell-cycle arrest and apoptosis have 
been found to be important. Garlic OSC’s to include ajoene (Li et al. 2002; Dirsch et al. 
2002), DATS (Kim et al. 2007; Xiao et al. 2004), DADS (Filomeni et al. 2003; Das et al. 
2007; Yang et al. 2009), and allicin (Kim et al. 2008) have been found to induce G2/M cell- 
cycle arrest in a number of different cell-lines. Apoptosis induction through the mitochondrial 
(intrinsic) pathway  has been observed in cancer cell-lines treated with ajoene (Li et al. 2002; 
Dirsch et al. 2002), DATS (Kim et al. 2007; Xiao et al. 2004), DADS (Filomeni et al. 2003; 
Das et al. 2007; Yang et al. 2009), and allicin (Kim et al. 2008). Although apoptosis through 
the death receptor (extrinsic) pathway has not been as extensively investigated, it has been 
found to not play a role in the case of ajoene-treated HL-60 leukemic cells (Dirsch et al. 
2002), but was found to be activated in DADS-treated HCT-15 human colon cancer cells 
(Yang et al. 2009) and allicin treated PC-3 human prostate cancer cells (Kim et al. 2008). 
Furthermore, the activation of c-Jun N-terminal Kinase-1 (JNK1) has been shown in DADS-
treated T98G and U87MG glioblastoma cells (Das et al. 2007) and in the SH-SY-5Y 
neuroblasoma cell-line (Filomeni et al. 2003). Protein thiolation and Reactive Oxygen 
Species (ROS) production also appear to be important for the in vitro anti-cancer activity of 
OSC; features discussed in greater detail in sections 1.6 and 1.7 respectively. 
1.4.3. In vivo anti-cancer activity of OSC  
In vivo studies have revealed that ajoene is effective in treating skin carcinomas in both 
rodents and humans. Topical application of ajoene to a chemically induced skin tumour in 
mice were found to almost completely inhibit tumour growth (Nishikawa et al. 2002), and 
application of ajoene to humans with basal cell carcinomas was found to reduce the tumour 
size in 81% of patients (Tilli et al. 2003). Another study on a melanoma tumour model in 
mice showed that intraperitoneal injection (IP) of ajoene (25 mg/kg) reduced tumour size 
three-fold and strongly inhibited metastasis to the lung (Taylor et al. 2006). 
For DADS, there is data to demonstate that gastric intubation of 1 mg DADS thrice weekly 
causes a reduction in HCT-15 human colon tumour volume by 69%, which was found to be 
further enhanced with IP injection of 0.5 mg DADS. Furthermore, the mice experienced no 
notable side-effects when treating with DADS (Sundaram & Milner 1996b). In another study, 
leukemic mice treated with 25 μM/100 μl DADS via IP injection were found to experience a 




usually associated with an increase in the size of the liver and spleen of mice, although mice 
treated with DADS had a liver size similar to that of the controls (Yang et al, 2006). 
DATS in vivo anti-cancer activity has been reported for the human colon cancer xenograft in 
a mouse model. Here, it was found that the mean tumour size, measured at 27 days after the 
transplantation of the xenograft, was 70 % larger in the control mice compared to the mice 
treated with 6 mg/kg DATS. DATS-treatment was found to not affect body weight or induce 
notable side-effects (Hosono et al, 2005). 
Thiosulfonate compounds are not reported to be found in garlic extracts, although they are 
reported to be found in cauliflower (Brassica oleracea L). It has previously been shown that 
the cauliflower-derived thiosulfonate, S-methylmethane thiosulfonate (S-MMTS) (Figure 
1.5), is able to significantly  reduce colon cancers in both rat and mice animal models at 80 
ppm either alone or in combination with sulindac, another experimental anti-cancer drug 
(Kawamori et al. 1995; Reddy et al. 1999). 
 
Figure 1.5. The chemical structure of S-methylmethane thiosulfonate (S-MMTS), an OSC anti-cancer 
compound isolated from cauliflower, which is reported to have in vivo anti-cancer activity against 
both mice and rat models with colon cancers (Kawamori et al. 1995; Reddy et al. 1999). 
 
1.4.4. Structure-activity based OSC studies  
Previous structure-activity based studies by Hunter et al. (2008) have shown that synthetic 
ajoene analogues, with substituted R
1 
groups, display varying anti-cancer activities; as seen 
by the IC50-values obtained against transformed CT-1 fibroblast cells (Table 1.2).  Here it 
was observed that the Z-isomers were marginally more active than the corresponding E-
isomers. Compound 13, in which R
1
 was substituted for p-methoxybenzyl, was found to be 






Table 1.2. The IC50’s of ajoene analogues with substituted R
1
 groups against CT-1 fibroblast cells 












2 Z-ajoene 15.5 




4 Z-propyl 17.0 








7 Z-OH 22.8 




9 Z-OPMB 21.7 




11 Z- phthal 34.6 








To further understand the structure/anti-cancer activity relationships in ajoene, Kaschula et 
al. (2012) synthesised a range of ajoene variants and tested them for their in vitro anti-cancer 




ajoene was varied for propyl and/or methyl, the anti-proliferative activity against WHCO1 
oesophageal cancer cells was retained, indicating that the ajoene pharmacophore does not 
reside within the terminal allyl groups. In contrasts, Sundaram & Milner (1996a) observed 
that when the terminal allyl groups of DADS is substituted for propyl to yield dipropyl 
disulfide (DPDS) (Table 1.4), the compound is ineffective at inhibiting the growth of human 
colon, skin and lung cancer cells. It would therefore appear that there is an underlying 
difference between the anti-proliferative activity of ajoene and DADS with respect to side-
group functionality. Furthermore, Kaschula et al. (2012) observed increased anti-proliferative 
activity against WHCO1 cells when the terminal allyl groups of ajoene were substituted with 
electron-rich end groups such as p-methoxybenzyl (E/Z-4l), resulting in a compound 12-fold 
more active than ajoene. The IC50 of E/Z-4l, which is 2.1 μM against WHCO1 cells, falls 
within the in vitro clinical range of two other oesophageal cancer chemotherapeutics namely 
cisplatin and 5-fluorouracil, whose IC50’s are 9.2 μM and 7.9 μM respectively against the 
same cell-line. These findings indicate that although the terminal allyl groups of ajoene are 
not critical for their anti-proliferative activity against WHCO1 cells, they do appear to play 
an important modulating role. In support of the hypothesis that the ajoene pharmacophore 
resides within the disulfide functional group, it was shown that ajoene analogues, E/Z-5, Z-6 
and E-6 (Table 1.3), that lack the disulfide bond, are inactive at inhibiting the proliferation of 
WHCO1 cells. This result is possibly supported by the literature report that DAS and S-allyl 
cysteine (Table 1.4), both monosulfides, are ineffective at inhibiting the growth of human 
colon, lung and skin cancer cells (Sundaram & Milner 1996a; Sundaram & Milner 1996c). 
Interestingly, the ajoene analogue E/Z-3l, containing an intact vinyl disulfide pharmacophore, 
but lacking the sulfoxide, was found to be three-fold more active than E/Z-4l returning an 
IC50 of 700 nM, implying that the sulfoxide group is not critical for the anti-cancer activity. 
Analogue 7, which contains the disulfide pharmacophore, but lacks both the sulfoxide and 
vinyl group, was found to be inactive, implying some synergy between the two groups. 
Mechanistic studies revealed that E/Z-4l, like its garlic-derived parent compound, induces 







Table 1.3. Chemical structures and IC50’s of ajoene analogues against WHCO1 oesophageal cancer 
cell proliferation (Kaschula et al. 2011; Kaschula et al. 2012). 
Ajoene and ajoene analogues 







































The water soluble counterpart of DADS, S-allylmercaptocysteine (SAMC) (Figure 1.6) is 
reported to be three-fold less active than DADS on human colon and leukaemia cells, 
indicating that some hydrophobicity may be needed for effective anti-cancer activity (Yang et 





Figure 1.6. Chemical structure of water-soluble DADS analogue, S-allylmercaptocysteine (SAMC) 
which displays three-fold decreased anti-cancer activity compared to DADS (Kwon et al. 2002; Xiao 
et al. 2005; Yang et al. 2009). 
 
In summary, it appears that the anti-proliferative activity of both ajoene and DADS relies on 
the presence of the disulfide functional group, and furthermore that the side groups at either 
end of the disulfide modulates the compounds anti-cancer activity. It seems likely therefore 
that the disulfide functional group may be the pharmacophore of the garlic-derived OSC.  
 
Table 1.4. The chemical structures S-allyl cysteine, as well as the synthetic DADS analogue, DPDS. 
S-allyl cysteine is an inactive compound, whereas DPDS is three-fold less active than DADS on the 
HL-60 leukaemia cell-line (Sundaram & Milner 1996a). 








1.5. The chemical reactivity of the disulfide bond: thermostability and kinetics 
Chemical reactivity between molecules is governed by both kinetic and thermodynamic 
parameters. In our study we propose that sulfenylation reactions and the generation of ROS 
may be important in the anti-cancer activity of OSC. We propose that the disulfide functional 
group of OSC may react with the cysteine nucleophile of a protein, resulting in the formation 
of an alkylated protein product and the expulsion of an anion leaving group. We further 
propose that the anion leaving group may react readily with free oxygen in the cell to 
generate ROS. During protein thiolation, activation energy is required to transform from its’ 
primary state to a transition state, which in turn is related to the kinetics of the reaction 




however since the incoming nucleophile is the same in all cases (cysteine thiol of a protein); 
the rate of reaction is dependent only on the accessibility of the incoming nucleophile to the 
electrophilic sulfur.  
 
Figure 1.7. Schematic of the equilibrium reaction between an OSC and the cysteine nucleophile of a 
protein to form the transition state and final product. Here, an incoming cysteine nucleophile reacts 
with the more electropositive sulfur of the disulfide, thereby leading to a mixed disulfide product and 
the expulsion of an anion leaving group. 
 
The thermodynamics of protein thiolation is driven by the stability of the products, which in 
our case, is largely governed by the stability of the negatively charged leaving group. The 
greater the ability of this leaving group to stabilise the anion, the greater the thermodynamic 
driving force and the more negative the ΔG (Gibbs free-energy) (Figure 1.8). Factors which 
increase stabilization of the leaving group include degree of conjugation, resonance and 
number of electronegative atoms. These effects are related to the theory that delocalised π-
electron systems present in aromatic rings impart increased stability. The different localised 
structures attempt to depict the real structure and are called resonance forms. Therefore, the 
more resonance forms available, the more stable the leaving group anion. 
In our thiolation hypothesis we propose that a free cysteine nucleophile reacts with the more 




with the expulsion of an anion leaving group. We further propose that this anion leaving 
group may then react with free oxygen in the cell to generate ROS. 
Although we can qualitatively assess the relative stability of the leaving group through its 
resonance, the extent of the leaving group stability can be quantitated through its pKa-value. 
The pKa-value is related to the acidity of the compound, whose strength is dependent on the 
stability of the conjugate base. This is highlighted in the examples of p-toluene sulfonic acid 
(Figure 1.9) and p-toluene sulfinic acid (Figure 1.10), where the former is a stronger acid than 
the later due to the increased stability of the sulfonic over the sulfinate anion. This is due to 
the superior resonance stabilisation of the negative charge acquired upon deprotonation by 















Figure 1.8. An exothermic energy diagram proposing the energy changes involved when an OSC 
reacts with a cysteine nucleophile in a protein to produce an alkylated protein and the expulsion of an 
























Figure 1.9. The deprotonation equilibrium reaction of p-toluene sulfonic acid. 
 
Figure 1.10. The deprotonation equilibrium reaction of p-toluene sulfinic acid. 
 
1.6. Protein thiolation 
Protein thiolation by OSC has been demonstrated in various cell-free systems.  A study by 
Krauth-Siegel et al. (1996) revealed, by X-ray crystallography, that the vinyl sulfur of ajoene 
(Figure 1.12) is able to react with glutathione reductase (GR), at Cys58 to produce an 
alkylated protein within the active site of the form allylSOCH2CH=CHSS(Cys58)-GR. A 
rationale for this interaction was proposed by Kaschula et al. (2011) where the allyl sulfur of 
ajoene was found to be the more electrophilic sulfur in view of the greater leaving ability of 
the vinylthio moiety in the disulfur exchange (Figure 1.11). In the model reaction, N-Boc-L-
cysteine ethyl was treated with the disubstituted p-methoxybenzyl ajoene derivative E/Z-41 to 
give p-methoxybenzyl N-Boc cysteine ethyl ester disulfide (Figure 1.13), indicating that the 
preferred site of attack in solution is at the non-vinyl sulfur. It is therefore likely that in the 
reaction between glutathione reductase and ajoene as observed by Krauth-Siegel et al. (1996), 
the product may have been observed as a result of a secondary reaction between the expelled 
sulfoxide/vinyl sulfide fragment and GR (Kaschula et al. 2011). In support of this, Lawson & 
Gardner (2005) have reported a reaction between excess cysteine (2eq) and ajoene to form a 
mixed disulfide ajocysteine product, S-allylcysteine.  
 
Figure 1.11. Proposed protein thiolation reaction between a yet to be identified protein target and E/Z 










Figure 1.13. Reaction demonstrating the chemical reactivity of the disulfide bond between an ajoene 
analogue and N-Boc protected cysteine methyl ester (Kaschula et al. 2012). 
 
Hosono et al. (2005) observed DATS-induced mitotic arrest and depolymerisation of 
microtubules in colon cancer cell-lines, which lead to them postulating that the protein, β-
tubulin, may be a drug target of DATS. Using Liquid Chromatography-Tandem Mass 
Spectrometry, they found that DATS is able to oxidatively modify β-tubulin at Cys-12β and 
Cys-354β in vitro through a mass increase of 72,1 Da, corresponding to S-
allylmercaptocysteine, a fragment molecule derived from DATS. It was thus concluded that 
DATS modification of β-tubulin may interfere with β-tubulin polymerisation, thereby leading 
to the observed delay in cell-cycle progression at the M-phase of the cell-cycle. 
1.7. Reactive oxygen species  
 1.7.1. Evidence for ROS in the in vitro anti-cancer mechanism of OSC 
Reactive oxygen species (ROS) are chemically reactive molecules containing oxygen, which 
usually have unpaired electrons or do not follow the octet rule. ROS form as a natural by-
product of normal oxygen metabolism and are important in cell signalling and homeostasis. 
However, under deregulated conditions, ROS are toxic and give rise to a condition termed 
oxidative stress which may induce deleterious effects like cell dysfunction and cell death. 
Evidence suggests that cancer cells exhibit higher levels of oxidative stress than their normal 
counterparts (Coussens & Werb 2002), supported by reports that markers of constitutive 




al. 1995). Increased levels of ROS production in cancer cells have been shown to arise 
through elevated levels of superoxide production, which is due to the low coupling efficiency 
of the mitochondrial electron transport with subsequent electron leakage. Here, excess 
superoxide has the potential to transform into more toxic ROS such as hydrogen peroxide 
(H2O2) and hydroxyl radicals (Pelicano et al. 2004) which may result in significant damage to 
cell structures. The highly oxidative state of cancer cells renders them vulnerable to agents 
that may increase their ROS levels further, resulting in a cascade of events leading to cancer-
cell death. Examples of cancer chemotherapeutics employing a ROS-generating mechanism 
include doxorubicin (Wang et al. 2004; Tsang et al. 2003), as well as garlic-derived OSC. 
OSC-induced cancer cell-death through increased ROS production and apoptosis has been 
extensively investigated in the family of garlic-derived OSCs. In vitro studies of ajoene-
induced apoptosis in HL-60 human leukaemia cells revealed that the anti-cancer mechanism 
involved ROS generation with the subsequent activation of nuclear factor kappa-light-chain-
enhancer of activated B cells (NFκB). Permeabilisation of the mitochondrial membrane, and 
the subsequent release of cytochrome c from the mitochondria was found to occur 
downstream of ROS production and NFκB activation, and was confirmed when pre-treating 
with the ROS scavenger N-acetyl cysteine (NAC), but not when pre-treating with the ROS 
inhibitor, catalase (Dirsch et al. 1998). This result appears to imply that either H2O2 is not one 
of the ROS species produced as a result of ajoene treatment or that though ROS is produced, 
it is not involved in the anti-cancer mechanism leading to cell death, and that NAC may be 
interfering with ajoene-induced cancer cell-death through a mechanism other than ROS 
production, a possibility discussed later in the Discussion section. 
A number of studies suggest that DAS either has minimal or no anti-cancer activity on most 
cell-lines (Hosono et al., 2005; Xiao et al, 2004; Xiao et al, 2005). Although, DAS, as well as 
DADS, has been shown to decrease cell viability in the glioblastoma cell-line; T98G and 
U87MG, with a significant increase in the levels of ROS production and subsequent p38 
mitogen-activated protein kinase (MAPK) activation, c-Jun N-terminal kinase-1 (JNK1) 
phosphorylation and apoptosis through the mitochondrial pathway, features which were 
abrogated when pre-treating cells with the ROS scavenger, ascorbate (Das et al. 2007).  
Kwon et al. (2002) observed a time-dependent increase in the levels of ROS production in the 
HL-60 leukemic cell-line treated with DADS. Here, ROS production peaked at 30 minutes 




cancer-cell death. DADS treatment resulted in caspase-3 activation and PARP cleavage, 
indicative of apoptosis, which were all blocked when pre-treating the HL-60 cells with 
catalase, indicating that increased levels of H2O2 is important in the anti-cancer mechanism  
of DADS in HL-60 cells (Kwon et al. 2002). When treating the A549 lung cancer cell-line 
with DADS, an early dose-dependent ROS event was also observed where ROS levels 
peaked 4 hours post-treatment. Pre-treatment with NAC completely abrogated the DADS-
induced apoptosis and cell-cycle arrest, indicating that ROS production occurs upstream of 
these events (Wu et al. 2005). Filomeni et al. (2003) evaluated the potential damaging effects 
of ROS production to macromolecules within the SH-SY5Y neuroblastoma cell-line. Here 
they observed increased lipid peroxidation subsequent to observing increased ROS 
production, which was significantly decreased in cells transfected with the anti-oxidant 
enzyme, human superoxide dismutase (hSOD), confirming a strict relationship between 
oxidative burst and the apoptotic response. Although, a G2/M cell-cycle arrest was still 
observed in the DADS-treated hSOD transfected cells, indicating that mechanisms other than 
ROS production may affect cell-proliferation in DADS treated SH-SY5Y cells.  
DATS, an OSC containing three sulfur atoms, also induces cancer-cell death through 
apoptosis. It was previously shown that when the LNCaP prostate cancer cell-line is treated 
with DATS, a dose-dependent increase in the levels of ROS was observed for up to 8 hours. 
Moreover, the non-cancer control prostate epithelial cell-line, PrEC, treated with relatively 
high levels of DATS, was found to display a significant delay in ROS production for 16 
hours. DATS treatment also caused apoptosis via the mitochondrial pathway with increased 
levels of cleaved caspase-9, disruption of the cristae in the mitochondria, elevated levels of 
cytosolic cytochrome c as well as decreased levels of the anti-apoptotic proteins; Bcl-2 and 
Bcl-xL. Lastly, pre-treating the LNCaP cells with NAC was found to almost completely 
protect against disruption of the mitochondrial membrane potential as well as cytoplasmic 
histone associated deoxyribonucleic acid (DNA) fragmentation. The authors therefore 
concluded that DATS-induced apoptosis in LNCaP cells correlated with ROS production 
(Kim et al. 2007). 
Diallyl tetrasulfide (DAS4) (Figure 1.14), a garlic-derived OSC with four sulfur atoms, is 
only present in low abundance in crushed garlic preparations and is therefore not as 
extensively studied for its anti-cancer properties as the OSC discussed previously, but has 
increased in vitro anti-cancer activity compared DATS, DADS and DAS (Kelkel et al. 2012). 




incubation of β-tubulin with DAS4 caused a significant increase in β-tubulin 
depolymerisation compared to the DMSO control. They also observed a correlation between 
β-tubulin depolymerisation and the number of sulfur atoms of the tested diallyl polysulfide: 
DAS4 exerts the strongest effects, followed by DATS, whereas DADS and DAS only barely 
affected β-tubulin depolymerisation. When treating the U937 histiocytic lymphoma cancer 
cell-line with DAS4, no changes in ROS levels were observed. Also, NAC, but not TROLOX 
was found to inhibit the anti-cancer activity of DAS4. In order to understand why NAC 
prevented DAS4-induced anti-cancer activity, the authors used a tubulin assay to test whether 
NAC interfered with DAS4-induced tubulin polymerisation. The authors showed that when 
the β-tubulin protein was co-incubated with DAS4 and NAC, the activity of DAS4 was 
inhibited, implying that NAC interferes with DAS4-induced tubulin depolymerisation, and 
not ROS per se (Kelkel et al. 2012). 
 
Figure 1.14. The chemical structure of diallyl tetrasulfide (DAS4), a garlic-derived OSC with four 
sulfur atoms, which has been shown to induce β-tubulin polymerisation in a cell-free system, and 
whose anti-cancer mechanism was shown to not involve ROS production in the U937 histiocytic 
lymphoma cell-line (Kelkel et al. 2012). 
 
In vitro anti-cancer mechanistic investigations of garlic-derived OSC provide evidence that 
although ajoene, DATS, DADS, DAS and allicin fall into different compound classes, there 
is much evidence to suggest that they act via a similar anti-cancer mechanism by inducing 
increased levels of ROS, cell-cycle arrest and eventually apoptosis. These findings therefore 
imply that these compounds may have similar targets in cancer cells, and we propose that this 
reactivity is linked to the presence of the disulfide/polysulfide/thiosulfinate functional group. 
1.7.2. ROS production mechanism 
Although ROS production has been implicated in the anti-cancer mechanism of garlic-
derived OSC, the cellular mechanism leading to ROS production is still unclear, although a 
number of hypotheses have been proposed. In a study by Gallwitz et al. (1999), it was shown 
that ajoene modification of glutathione reductase (GR) leads to the functional inactivation of 
the protein. Essentially, glutathione reductase is responsible for replenishing the 
concentrations of glutathione from glutathione disulfide within the cell, and it is proposed 




to glutathione disulfide may result in an imbalance in the redox state of the cell towards ROS 
burden (Gallwitz et al. 1999). This finding could support the anti-cancer mechanism in which 
a synergy exists between protein thiolation and increased ROS levels. 
Although one common explanation for the biological activity of OSC is their ability to react 
with protein thiols, the biochemical importance of the leaving group in the thiol-polysulfide 
reaction may also be important. Some consider the leaving group to be the actual active form 
of the polysulfide. The leaving group thiol or perthiol are reducing agents that may react 
rapidly with oxidants like dioxygen and oxyhaemoglobin to form ROS. A mixture of oxy-
/methaemoglobin in the presence of disulfides or polysulfides may convert dioxygen to H2O2. 
If the disulfide bond is flanked by at least one side-group that is electron withdrawing, i.e. the 
side-group weakens the disulfide bond, the disulfide compound will react more readily with 
potential protein targets, and furthermore, may also result in an increased ROS response.  
Another possibility is that OSC-induced ROS production may occur through the homolytic 
cleavage of the disulfide bond within polysulfides to generate a thiyl or perthiol radical. 
Antosiewics et al.(2006) has shown that DATS-induced ROS generation in DU145 and PC-3 
cells is caused by an increase in labile iron pool due to the degradation of ferritin mediated by 
JNK signalling. Labile iron is considered an important determinant of ROS generation in 
cells as even low concentrations of labile iron, and can cause oxidative stress through 
Fenton/Haber-Weiss reactions.  
1.8. Protein Disulfide Isomerase 
We propose that garlic-derived OSC induce their anti-cancer effects by forming mixed 
disulfides with protein targets within cancer cells, with the resultant generation of ROS. 
Mixed disulfide formation may lead to protein inhibition, which may affect cancer cell 
viability, possibility leading to apoptosis and cancer cell death. The proposed target protein 
should therefore have a free cysteine residue available for nucleophilic attack on the OSC, 
and the chemistry of the cysteine environment should also facilitate this reaction. Previous 
work in our laboratory has found co-localisation of a fluorescently-tagged ajoene analogue 
(DP) to the ER of cancer cells (Figure 1.15). Due to the prospective biochemical properties 
discussed below, we therefore intend to investigate Protein Disulfide Isomerase (PDI), an 




PDI, which forms part of the thioredoxin protein family, is an ER resident protein whose 
active site cysteine residues are involved in disulfide bond formation, isomerisation and 
reduction within newly synthesised proteins (Freedman et al. 1994). PDI was first isolated 
from liver in 1963 (Goldberger et al. 1963). Structurally, PDI has five domains (Figure 1.16), 
of which four (a-b-a’-b’) have thioredoxin folds made up of α-helices and β-strands (β-α-β-
α-β-α-β-β- α) (Kemmink et al. 1997; Ferrari et al. 1998), followed by a c-domain which does 
not have a secondary or tertiary structure (Kemmink et al. 1997). There are extensive internal 
sequence similarities between the a and a’ domains which each have a common active site  
sequence (-Cys-Gly-His-Cys-) (indicated in Figure 1.16) involved in the redox and 
isomerisation activities of PDI. The N-terminus cysteine residue of the a’-domain was shown 
to have a greater reducing capacity, and is thought to be responsible for the redox/isomerase 
activity of PDI with a pKa of 4.5, compared to the pKa of cysteine which is 8.0 at pH 7.0, 
indicating that the active site thiol is predominantly in a thiolate form at physiological pH, 
thereby more readily able to reduce its target. The low pKa of the cysteine thiol in the PDI 
active site is due to the partial stabilizing ability of the nearby histidine imidazole group 
within the active site, as well as the partial positive charge of the N-terminal of the α-helix 
after the N-terminal cysteine residue (Chivers et al. 1996; Vuori et al. 1992; Darby et al. 
1994; Wunderlich et al. 1995; Kortemme et al. 1996). Although the b- and b’-domains have 
thioredoxin-like folds similar to the a- and a’-domains, they do not have active site residues, 
and also have low sequence similarities. It has previously been reported that the b’- and c-
domains have low-affinity hydrophobic interactions with peptides or proteins as to assist with 
the correct positioning for catalysis by PDI (Noiva et al. 1993; Klappa et al. 1998). 
Furthermore, the c-terminus of PDI has an ER retention signal, which interacts with the ER 
membrane for localisation, with a Lys-Asp-Glu-Leu (KDEL) amino acid sequence, as 
indicated in Figure 1.16. 
PDI makes up ~ 0.8 % of total cellular protein (Freedman et al. 1994), reaching near 
millimolar concentrations in the lumen of the ER in some cells (Zapun et al. 1992). The 
redox potential of PDI is dependent on its environment, which is controlled by the ratio of 
oxidised to reduced glutathione in the ER (GSH:GSSG ≈ 2:1) (Hwang et al. 1992). The 
standard redox potential of PDI is about -180 mV (Hawkins et al. 1991). Furthermore, the 
oxidative environment of the ER supports the stability of the anion leaving group which 







           
Figure 1.15.The chemical structure of (a) DP, a fluorescent ajoene analogue, with an IC50 of 25 μM 
against MDA-MB-231 breast cancer cells are represented. Co-localisation between DP (blue) and an 
ER-tracker (red) in MDA-MB-231 cancer cell-line is shown with confocal images (b); row i represent 
cells treated with ER-tracker alone (red) (A) with no signal from the blue filter (B) as well as the 
representative phase contrast image (C). Row ii represents cells treated with DP (blue) (E) with no 
signal from the red filter (D) as well as the representative phase contrast image (F). Row iii represents 
cells treated with an ER-tracker (red) (G) and DP (blue) (H) with the representative images for phase 
contrast (I) and co-localisation (pink) (J) between the ER-tracker and DP. 
 
 
Figure 1.16. The structure of mammalian PDI. Domain boundaries as proposed by Darby et al. 
(1994) are noted. The location of the proposed peptide binding site and the C-terminal -KDEL ER-









Several compounds are known to inhibit PDI, to include bacitracin (Figure 1.17A), 5,5-
dithio-bis(2-nitrobenzoic acid) (DTNB) (Figure 1.17 B) as well as phenyl arsine oxide 
(Figure 1.17C). 
DTNB contains a disulfide functional group (encircled in Figure 1.17B) and is therefore 
structurally similar to the garlic-derived OSC, DADS. Although the mechanism of PDI 
inhibition has not yet been confirmed for DTNB, it is generally proposed that the disulfide 
functional group of DTNB may form a mixed disulfide with the active site cysteine residues 
of PDI, leading to the inhibition of PDI isomerase and its redox activities; the same 
hypothesis that we propose for PDI and garlic-related OSC. It has recently been confirmed 
that bacitracin inhibits PDI through mixed disulfide bond formation (Dickerhof et al. 2011). 
Using Matrix-Assisted Laser Desorbtion/Ionisation Time Of Flight Mass Spectromtery 
(MALDI-TOF MS), Dickerhof et al. (2011) showed that a direct interaction forms between 
an open thiol form of the bacitracin thiazoline ring (sulfur encircled in Figure 1.17A) and 
Cys314 and Cys345 residues in the substrate binding domain of PDI, leading to the inhibition 
of PDI isomerase and redox activities.  
 
 
     
Figure 1.17. The chemical structures of PDI inhibitors; bacitracin from bacillus licheniformis (A), 








We propose that the garlic-derived OSC inhibit the redox and isomerase activities of PDI by 
forming mixed disulfides with the PDI active site residues, the result being that the protein 
substrates of PDI do not form their proper tertiary structure. We therefore propose that the 
anti-cancer mechanism of OSC may occur through PDI thiolation within the active site to 
possibly disrupt protein folding, with the concurrent generation of ROS, which may lead to 
apoptosis and cell death. 
1.9. Analogues of garlic-derived OSC 
For the Masters project, a small library of thiosulfonates and a thiosulfinate (Figure 1.18) as 
well as disulfides (Figure 1.19) were designed and synthesised in the Chemistry Department 
at UCT by Post-Doctoral student, Dr. Nashia Stellenboom. The compounds were used to 
probe the structure / anti-cancer activity relationships for this class of compounds. It was 
envisaged that increased electrophilicity of the sulfur atom in the OSC and/or increased 
stability of an expelled anion leaving group may favour both protein thiolation and ROS 
production to thereby generate a more reactive analogue with a lower IC50-value. The 
thiosulfonates are completely synthetic analogues of garlic-derived OSC, although a natural 
product thiosulfonate, S-MMTS (Figure 1.4) is reported to be present in cauliflower and has 
also been found to display in vivo anti-cancer activity (Kawamori et al. 1995; Reddy et al. 
1999). The thiosulfinate and disulfides are structural variants of the parent compounds, allicin 
and DADS respectively, which are found naturally in crushed or processed garlic. 
Apart from the key disulfide or an “activated disulfide” group being present, we have 
additionally inserted various side groups with either electron withdrawing or/and electron 
donating character. Since it has previously been found that increased lipophilic character is 
related to enhanced activity (Kaschula et al. 2012), a lipophilic analogue (NSZ) and a water-
soluble analogue (92), were also included in the series. Random numbers were previously 











































Figure 1.18. List of thiosulfonate and thiosulfinate compounds used in the study. Compounds 
include t-benzyl, t-fluoro, t-PMB, t-propyl and Allicin-16. 
Disulfides 



















Figure 1.19. List of the disulfide analogues used in the study. These include those with electron 
withdrawing side-groups: 21, 200, 30, 16; compounds with neutral side-groups:  8, 2, NSZ, compound 






We hypothesise that the pharmacophore of garlic disulfide compounds, and related 
compounds, is the disulfide functional group, and that these compounds exert their anti-
cancer effects through increased ROS production and protein thiolation, where PDI may be a 
potential protein target. We also hypothesise that the anti-cancer activity of the disulfide may 























The objectives are to carry out a structure-anti-activity assessment of a small library of 
disulfide, thiosulfinate and thiosulfonate compounds against WHCO1 oesophageal cancer 
cells. If the classes of compounds are found to be active, the mechanism of action of two 
compounds, one from the disulfide and one from the thiosulfonate compound class, will be 
selected for further evaluation to include cell-cycle analysis, ROS production, apoptosis 
induction and morphological changes. 
If ROS production is found to be important, we will assess whether the anti-proliferative 
activity is dependent on ROS generation using ROS scavengers. 




















Investigating structure-anti-proliferation relationships of DADS and 
thiosulfonate compounds in WHCO1 oesophageal cancer cells 
 
2.1. Introduction 
Organosulfur compounds (OSC) from garlic which are reported to have in vitro and in vivo 
anti-cancer activity share common structural features to include either a disulfide or 
polysulfide backbone. It is hypothesised that the disulfide or polysulfide functional group of 
OSC may react with the free cysteine nucleophile within a target protein, resulting in the 
formation of alkylated protein product and the expulsion of anion leaving group. The 
alkylated protein may therefore be unable to perform its proper cellular function, potentially 
leading to the deregulation of protein pathway signals and eventually cell death. 
In the current chapter, we assessed the structure-anti-proliferation relationships in a small 
library of 10 diallyl disulfide (DADS) analogues, 4 thiosulfonate compounds, a compound 
class not reported to be found in garlic, and 1 allicin analogue against WHCO1 oesophageal 















2.2.1. Cell viability (MTT assay) 
To assay for the ability of thiosulfonate compounds and DADS analogues to inhibit cancer 
cell viability, an MTT assay was performed. The MTT assay is a colorimetric assay which is 
based the conversion of MTT to formazan by metabolically active cells. WHCO1 cells were 
seeded in 96-well plates and treated with either a thiosulfonate or disulfide analogue at 
concentrations varying from 0 to 200 µM for 48 hours. The cells were then treated with the 
MTT reagent for 4 hours after which they were lysed to solubilise the crystalline MTT, and 
the relative absorbance was quantified at 595 nm using a multi-plate reader. Independent 
triplicate experiments were performed. The absorbance obtained was fitted against 
concentration to generate a dose-response curve, from which an inhibitory IC50 concentration 
was obtained, defined as the concentration of the compound required to inhibit the viability 
of 50% of the cells after 48 hours. 
The IC50’s obtained against WHCO1 cell proliferation are displayed in Table 2.1 and Table 
2.2 alongside their respective chemical structures together with a representative IC50 curve. It 
is evident that the thiosulfonate compounds as well the DADS analogues; 2, 21, 200, 30, 54, 
46 and 59 all decreased WHCO1 cell viability after a 48 hour treatment. The four 
thiosulfonate compounds were all found to be equally active, with an IC50 around 15 µM. The 
disulfides exhibited a broader range of activities from 5 µM to inactive (IC50 > 200 µM). The 
most active disulfide was found to be 54 with an IC50-value of 4.87 µM, which is ~ 10-fold 
more active than the parent, diallyl disulfide (DADS). On the other side, compounds NSZ, 
92, 8 and 16 were all found to be inactive. Allcin-16, an OSC analogue whose IC50 was 
previously determined in our lab (unpublished data), was found to be active with an IC50 of 
71.1 μM and was included in the series for comparison as, it belongs to a different compound 








Table 2.1. List of thiosulfonate compounds, with their respective chemical structures and a 
representative IC50 curve obtained by the MTT colorimetric assay against WHCO1 cell proliferation. 
Compound  
Name 
Chemical structure Dose –Response Curve 
WHCO1 


























Unpublished data from our laboratory. 
 
WHCO1 cells treated with t-benzyl 2

























WHCO1 cells treated with t-fluoro 2

























WHCO1 cells treated with t-PMB

























WHCO1 cells treted with t-propyl 2






















































Table 2.2. List of diallyl disulfide (DADS) analogues, with their respective chemical structures and 
representative IC50-curves obtained through the MTT colorimetric assay on WHCO1 cells. 
Compound 
Name 
Chemical structure Dose-response curve 
WHCO1 


























WHCO1 cells treated with compound2

























WHCO1 cells treated with compound 200

























WHCO1 cells treated with compound 30
























WHCO1 cells treated with 21






1.0 IC50 = 17.86 uM
















WHCO1 cells treated with compound 54

























WHCO1 cells treated with NSZ






























Table 2.2. continued. List of diallyl disulfide (DADS) analogues, with their respective chemical 




Chemical structure Dose-response curve 
WHCO1 




















95 ± 0.38  
 
2.2.2. Predictive pKa-values of OSC leaving groups 
We propose that in a reaction between a free cysteine thiol of a protein and an OSC 
containing a disulfide functional group, the cysteine thiol will act as the incoming nucleophile 
WHCO1 cells treated with compound 92



























WHCO1 cells treated with compound 8
























WHCO1 cells treated with compound 16
























WHCO1 cells treated with compound 46


























WHCO1 cells treated with compound 59





























to form a mixed disulfide with the OSC, with the expulsion of an anion leaving group. We 
hypothesise that an OSC having a more stable leaving group will result in a more 
thermodynamically favoured reaction. The leaving group stability can be assessed 
qualitatively through resonance predictions (see Discussion), and quantitatively by assessing 
its pKa-value. Using the Pipeline® predictive programme, the predictive pKa-values were 
computer generated for each leaving group as shown in Table 2.3. The thiosulfonate leaving 
group was the same for all compounds in its class and had a predicted pKa-value of 6.82, 
whereas the predicted pKa-values for the DADS analogues varied greatly from 2.71 for 200 
to 10.53 for NSZ. To determine if a relationship exists between the measured IC50-values and 
the predicted pKa-values for the various DADS analogues, compounds 200, 30, 21 and 2 
were selected for correlation studies as their left side-groups are all propyl. A scatter plot of 
the predicted pKa-value and log IC50-values is shown in Figure 2.1 with an R
2
-value of 0.88. 
Table 2.3. The chemical structures of selected DADS analogues and their respective leaving groups, 
alongside their respective IC50-values and predicted pKa-values which were determined using the 
















































Figure 2.1. Scatter plot of log IC50 vs predicted pKa for DADS analogue leaving groups. A 

















































Thiosulfonate series: The MTT results for thiosulfonates show that they all had similar 
activities with IC50’s ~ 15 µM (Table 2.1). This could be explained due to the probability that 
the electronic effects of benzyl-, fluoro-, para-methoxybenzyl- and propyl-side-groups on the 
benzyl group are not able to modulate the electronics of the thiosulfonate or the stability of 
the leaving group due to the presence of the sp
2
 carbon which separates these side groups 
from the thiosulfonate functional group. The sp
2
 carbon prevents the transfer of resonance 
from the ring to the thiosulfonate. The thiosulfonate itself is an activated disulfide due to the 
presence of the two oxygen atoms which present an electron-withdrawing effect on the 
adjacent sulfur, which may be activated to nucleophilic attack from a cysteine residue within 
a protein (Figure 2.2). The finding that the IC50 remained unchanged between the analogues 
with the same functional group implied that it was solely the presence of the reactive group 
that confers activity, and that the side-groups did not have any modulatory effect, resulting in 
a low IC50 of 15 μM.  
 
Figure 2.2. The proposed reaction between a cysteine nucleophile and the more electropositive sulfur 
of the thiosulfonate, resulting in the formation of a mixed disulfide between the sulfur of the 
thiosulfonate and the cysteine residue of the protein, with the expulsion of the anion leaving group. 
 
Disulfide series: For this series of compound, a correlation was observed between the IC50 
and the degree of resonance stabilization of the leaving group anion. The IC50 of 200 (9.9 
µM) was found to be ~2.5-fold lower than 30 (22.3 µM). The leaving group, of both 30 and 
200, have 4 resonance forms (Figure 2.3 and Figure 2.4 respectively), however the negative 
charge acquired by the pyridine leaving group of 200 is more stable than the negative charge 
acquired by the p-nitrobenzene leaving group of 30 due to the presence of the electronegative 
nitrogen in the ring being endocyclic in the pyridine of 200 compared to the nitro group being 
exocyclic in p-nitrobenzene in 30, conferring greater anion stability to 200. This explanation 
in terms of resonance is also supported quantitatively by the predicted pKa’s which were 




The DADS analogue, 54 was found to be the most active disulfide in the series with an IC50 
of 4.87 μM. Similar to 21, it has a heteroaromatic benzothiazole side-group. It is 
hypothesised that in the reaction with cysteine, the heteroaromatic benzothiazole anion in 
both the cases of 54 and 21 is expelled as the leaving group. The heteroaromatic 
benzothiazole anion has six resonance forms (Figure 2.5), resulting in the highest number of 
resonance forms in the series. The difference in IC50 between 21 (23 μM) and 54 (4.87 μM) 
must therefore be due to the presence of the long hydrophobic chain containing lipophilic 
fluorines in 54 which are predicted to increase the lipophilicity leading to a more active 
compound. Contrary to resonance theory, 21, with 6 resonance forms, has a higher IC50 (23.0 
μM) when compared to 200 and 30 (10 and 20 μM respectively), which have 4 resonance 
forms. According to the predictive pKa-value of the heteroaromatic benzothiazole side-group 
of 21, which is 6.93, 21 should be less active than both 200 and 30, whose leaving groups 
have pKa-values of 2.71 and 4.60 respectively. The predictive pKa results therefore suggest 
that the heteroaromatic benzothiazole side-group is actually less stable than resonance would 
suggest and are in-line with the IC50 data. Furthermore, 2 and NSZ, whose IC50’s were 61.1 
and > 200 μM respectively, had pKa-values of 8.82 and 10.53, which predict a much less 
active compound based on leaving group stability and correlates well in a linear plot of 




Figure 2.3. The four different resonance forms of the leaving group anion of 30. The arrows in and 







Figure 2.4. The four different resonance forms of the anion leaving group of 200. The arrows in and 
around each resonance form indicates the movement of electrons and charge around the molecule. 
 
The leaving group in compounds 2 and 8 is the same, with three possible resonance forms 
(Figure 2.6), indicating that the thermodynamic driving force should be equal for both 
compounds. However, 8 was found to be inactive, and 2 has an IC50 of 61.1 µM. This may be 
due to the presence of the bulky t-butyl group of 8, which is substituted with a propyl group 
in 2. The bulky t-butyl group of 8 likely introduces some steric hindrance to the incoming 
nucleophile, thereby affecting the reaction kinetics between 8 and the cysteine nucleophile. 
 
 
Figure 2.5. The six different resonance forms of the benzothiazole leaving group of 54 and 21. The 







Figure 2.6. The three different resonance forms for the leaving group anion of both compound 2 and 
8. The arrows in and around each resonance form indicates movement of electrons and charge around 
the molecule. 
 
In comparing the structures of 8 and 16, the difference being that 16 has an exocyclic methyl 
benzoate group on its benzene ring and 8 does not. The exocyclic methyl benzoate group of 
16 has an electron withdrawing effect on its disulfide group. The leaving group of 16 has four 
resonance forms (Figure 2.7), and 8 has three (Figure 2.6), indicating that the leaving group 
of 16 is more stable compared to 8. Both compounds are however inactive, possibly due to 
the steric hindrance of t-butyl group, preventing nucleophilic attack from an incoming 
cysteine nucleophile. It is possible that these predicted selectivity’s could possibly be 
observed if assaying was carried out at a higher concentration. 
Allicin-16 has a similar structure to 16, with the exception that allicin-16 is a thiosulfinate, 
compared to 16 which is a disulfide. Allicin-16s stronger activity, with an IC50 of 71 µM, 
compared to 16 which was inactive (IC50 > 200 µM), supports the hypothesis that the 
presence of the oxygen on allicin-16 enhances its anti-cancer activity by activating the 
disulfide towards thiolation.  
Compound 46 has mixed characteristics in which one side-group is electron withdrawing and 
the other is electron donating. The methyl benzoate group is possibly the leaving group of 46 
due to its electron withdrawing ability and the existence of four resonance forms (Figure 2.7).  
Compound 59 is unique in the series as it is the only compound that has an electron-
withdrawing group on either side of the disulfide. Both side groups of 59 are therefore able to 
stabilise an anion. The pyridine group is possibly the better leaving group due to the presence 
of an endocyclic nitrogen (Figure 2.8). It would be anticipated that the IC50 of 59 should have 




the IC50 was found to be 95 μM, which could possibly be explained on kinetic grounds where 
the bulky methyl benzoate group may provide steric hindrance towards the incoming 
nucleophile. This reaction may be too slow in the timeframe of the experiment, resulting in 
decreased activity. 
NSZ was found to have an IC50 greater than 200 µM, which is not unexpected based on the 
absence of stabilising side groups in this compound. A similar finding was observed when the 
allyl side-groups of DADS were substituted for propyl (Sundaram et al, 1996). A rationale 
for this observation was not described, but our results indicate that the loss of activity of 
DADS with propyl side-groups could be due to propyl being a poor leaving group, as it 
cannot stabilise an acquired negative charge. This may be because the attack of a cysteine 
nucleophile on the disulfide bond of DADS does not generate a leaving group that can 
stabilise the expelled negative charge, therefore the reaction is not favoured (Figure 2.9, ii). 
In comparison, dipropyl ajoene which contains a vinyl disulfide functional group may 
generate a leaving group (Figure 2.9, i) hence conferring activity to dipropyl ajoene but not 
dipropyl disulfide. So, instead of this reaction being exothermic as that which we could 
expect for 54, the reaction for NSZ may be endothermic.  
 
Figure 2.7. The four different resonance forms for the leaving group anions for compounds 46, 16 
and allicin-16, methyl benzoate. The arrows in and around each resonance form indicates the 





Figure 2.8. The four different resonance forms of the leaving group anion for 59. The arrows in and 
around each resonance form indicate the movement of electrons and charge around the molecule. 
 
Compound 92, which is hydrophilic compared to the other compounds, was found to be 
inactive with an IC50 greater than 200 µM. The high IC50 obtained is not surprising as it has 
previously been reported that the water-soluble counterpart of DADS, S-
allylmercaptocystine, is three-fold less active against human colon cancer and leukaemia cell-
lines (IC50 = 150 µM) (Yang et al, 2009; Kwon et al, 2002; Xiao et al 2003). The hydrophilic 
character of compound 92 may prevent it from crossing the lipophilic membranes of cells, 
and is therefore unable to carry out its potential anti-cancer effects. 
 
Figure 2.9. A schematic of the chemical reaction of (i) dipropyl ajoene and (ii) dipropyl disulfide 




In summary, there appears to be a correlation between thermostability of the leaving group 
anion of the disulfide and the potency of the compound at inhibiting proliferation of WHCO1 
cells. It is also apparent that steric hindrance of side-groups about the disulfide 
pharmacophore appears to decrease the activity of the compound. It appears that a degree of 
lipophilicity is required for the compounds to be active. The strength of activity for this series 
of disulfide compounds appears to correlate to the stability of the leaving group anion which 
is shown in order of decreasing stability. Furthermore, the predicted pKa-value for each 
leaving group, which served as a quantitative means to determine leaving group stability, 
showed a correlation between leaving group stability and the IC50 for the corresponding 
compound. 
The data generated in this study strongly support the hypothesis that garlic OSC compounds 
act as thiolating agents to proteins in WHCO1 cancer cells and that the mechanism of 

















Investigating the in vitro anti-cancer mechanism of t-PMB and 200 in 
WHCO1 oesophageal cancer cells 
 
3.1. Introduction 
Evidence from the literature into the in vitro anti-cancer mechanism of OSC-induced cancer 
cell death show that although ajoene, allicin, DATS, DADS and DAS fall into different 
compound classes, they appear to act via a similar mechanism in cancer cells; by inducing 
increased levels of ROS and cell-cycle arrest, with the end result being apoptosis. Thus, it is 
likely that these compounds may have similar targets in cancer cells, and we hypothesise that 
this reactivity is linked to the presence of the disulfide/polysulfide/thiosulfinate functional 
group.  
For our study, one thiosulfonate and one DADS analogue was selected for further 
mechanistic analysis. The compound selected from the DADS group was 200, with an IC50 of 
9.9 μM, as we had a considerable amount of the compound and it had a lower IC50 compared 
to other DADS analogues. Since the IC50’s for all analogues within the thiosulfonate group 
were similar in the range of 15 µM, any could be opted for, but we selected t-PMB based on 
the amount of material available. The anti-cancer mechanism of t-PMB and 200 were 
evaluated by assessing morphological changes in treated cells, and assaying whether the 
compounds induce apoptosis and cell-cycle arrest. Furthermore, a ROS assay was employed 
to determine whether treatment with t-PMB or 200 resulted in increased levels of ROS, 











3.2.1. Proliferation assay (BrdU assay) 
The MTT assay measures cell viability, and therefore indirectly measures cell proliferation. 
To confirm that compounds t-PMB and 200 are in fact inhibiting cell proliferation, the BrdU-
cell-proliferation assay was used. This assay directly measures cell-proliferation by 
quantitating the incorporation of tagged uracil into newly synthesised DNA. For the assay, 
WHCO1 cells were treated with 2 × IC50 of t-PMB (30 μM) or 200 (20 μM) for 48 hours, 
with negative controls being cells in media alone or cells treated with the vehicle alone (0.1 
% DMSO in media). All experiments were performed in quadruplicate, and significance 
differences were assessed using the student t-test. In agreement with the MTT assay, 
complete inhibition of cell proliferation was observed when treating with 2 × IC50 of both t-




Figure 3.1. Cell proliferation determined through the BrdU assay performed on WHCO1 cells 
treated with t-PMB and 200. WHCO1 cells were treated with 2 × IC50 of t-PMB or 200 for 48 hours 
and cell proliferation was measured using the BrdU assay. Cells in media alone or cells treated with 
0.1 % DMSO in media, were used as negative controls. The data was recorded in quadruplicate and 
are indicated with standard deviations, and significant changes are highlighted (*** indicates p-value 
< 0.005; **** indicates p-value < 0.001; NS indicates No Significance). 
 
3.2.2. Cytotoxicity of t-PMB and 200 in tumour and non-tumour cell-lines 
The cytotoxicity of t-PMB and 200 was assessed by comparing the IC50’s obtained against 







































Het1A, which is a non-cancer cell-line of oesophageal epithelial origin, immortalised with the 
SV40 large T antigen (Het-1A [Het1A] ATCC® CRL-2692™). The 24-hour IC50 against 
WHCO1 cells, which was obtained in independent triplicate experiments, was found to be 
25.6 μM for t-PMB and 21.6 μM for 200 (Table 3.1), with dose-response curves displayed in 
Table 3.2. The 24-hour-IC50’s for t-PMB and 200 against WHCO1 cells were found to be 
about 2-fold higher than their 48-hour IC50’s, indicating that both compounds exert a greater 
inhibitory effect at 48-hours compared to 24-hours. As shown in Table 3.1, the 24-hour IC50’s 
of t-PMB and 200 against Het1A cells, obtained in independent triplicate experiments,  were 
found to be 64.8 μM and 206 μM respectively, indicating that t-PMB was 2.5-fold more 
selective, and 200 was 10-fold more selective, to the WHCO1 oesophageal cancer cell-line 
over Het1A non-cancer control cell-line. The dose-response curves for t-PMB and 200 on 
Het1A cells are displayed in Table 3.2.  
 
Table 3.1. The 24-hour IC50-values (µM) for 200 and t-PMB against WHCO1 and Het1A 






IC50 ± SD (µM) 
Het1A 
24-hour 









21.6 ± 1.5 206.1 ± 15.1 10 
 
In order to ascertain whether t-PMB and 200 are also toxic to other cancers, the 48-hour 
IC50’s of t-PMB and 200 were also determined against A375 human melanoma cells, and 
were found to be 2.27 μM for t-PMB and 3.17 μM for 200 (Table 3.3) for triplicate 
independent experiments. This data reveals that these compounds are ~ 4-fold more selective 






Table 3.2. The 24-hour dose–response curves for t-PMB and 200 on the WHCO1 oesophageal cancer 
cells and Het1A cells are displayed.  






Table 3.3. The dose-response curves and 48-hour IC50-values of t-PMB and 200 against A375 human 
melanoma cell proliferation obtained in independent triplicate experiments. 
Compound  
Name 
Chemical structure Dose-response curve 
A375 








3.17 ± 0.4 
 
3.2.3. Morphology 
The morphology changes in WHCO1 cells treated with t-PMB or 200, at 2 × their respective 
48-hour IC50-values, were assessed through phase contrast images at 1000 × magnification, 
which were captured at time intervals; 0, 24 and 48 hours post-treatment (Figure 3.2). The 
morphology images show that some of the cells treated with either t-PMB or 200 for 24 
WHCO1 cells treated with t-PMB
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hours appear to have condensed and rounded-up, with no defined nucleus and a few cells 
appearing to have lysed (indicated by the arrow in Figure 3.2), features indicative of 
apoptosis. These features were found to be present in more cells 48-hours post-treatment with 
both compounds. All of the cells adopted this morphology in the 48-hour samples, which is to 
be expected as cells were treated with 2 × 48-hours IC50 concentrations. 




















Figure 3.2. Phase contrast images of WHCO1 cells treated with 2 × 48-hour IC50 of either t-
PMB or 200 for 0, 24 and 48 hours. To determine whether treatment with either t-PMB or 200 at 2 
× their respective 48-hour IC50’s caused changes in WHCO1 cellular morphology, phase contrast 
images of treated and untreated cells were taken at 0, 24 and 48 hours at 1000 × magnification. 
Images A, B and C represent the negative controls with WHCO1 cells in media alone for 0, 24 and 48 
hours respectively. Images D, E and F represent the negative control where WHCO1 cells were 
treated with the vehicle, 0.1 % DMSO in media, at times 0, 24 and 48 hours respectively. Images G, 
H and I represent WHCO1 cells treated with t-PMB at twice the 48-hour IC50 (30 μM) for 0, 24 and 
48 hours respectively. Images J, K and L represent WHCO1 cells treated with 200 at twice its 48-
hour IC50 (20 μM) for 0, 24 and 48 hours respectively. The arrow highlights a cell that has condensed 
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3.2.4. Cell-cycle analysis  
Fluorescence activated cell sorting (FACS) analysis was performed to determine whether t-
PMB or 200 elicit any changes to the cell-cycle in WHCO1 cells. Cell-cycle analysis was 
performed on WHCO1 cells at 0, 6, 12 and 24 hours post-treatment using 2 × 24-hour IC50 
concentrations of t-PMB (52 μM) or 200 (40 μM). Data were compared to the negative 
controls of WHCO1 cells treated with 0.1 % DMSO in media or media alone. Propidium 
iodide (PI) was used to stain the DNA of cells fixed with 70% ethanol. Since PI stains 
ribonucleic acids (RNA) and DNA, the cell lysate was treated with RNase A to remove the 
RNA. Once the DNA was stained, fluorescence was measured at 480 nm, and the cells were 
grouped according to cell-cycle phase. Over 10000 cells were counted per analysis which is 
the minimum requirement for FACS analysis. The percentage of coefficient of variance (% 
CV) was set at 8 % for significance. For all samples tested, the % CV was found to be below 
8 %. For WHCO1 cells treated with either t-PMB (Figure 3.3 and 3.4) or 200 (Figure 3.5 and 
3.6), a time-dependent increase in the number of cells arrested in the G2/M-phase of the cell 
cycle, with a concurrent decrease in the population of cells in the S- and G1-phases, were 
observed. An increase in the amount of debris formed after the 24-hour treatment was also 
observed, indicative of cell lysis.  
 
 
Figure 3.3. Populations of cells in the S, G1 and G2 phases of the cell-cycle in WHCO1 cells 
treated with t-PMB. To determine whether t-PMB induced cell-cycle arrest in WHCO1 cells, cells 
were treated with t-PMB at 2 × 24-hour IC50 concentration (52 μM), and FACS analysis was 






























0 hours 6 hours 
 
 
12 hours 24 hours 
Figure 3.4. Cell-cycle profiles of WHCO1 cells treated with t-PMB in a time-dependent manner. 
WHCO1 cells were treated with 2 × 24-hour IC50 of t-PMB (52 μM) for 0, 6, 12 and 24 hours for 
FACS analysis. A time-dependent increase in G2/M cell-cycle arrest was observed, with a concurrent 
decrease in the G1- and S-populations. 
 
 
Figure 3.5. Populations of cells in the S, G1 and G2 phases of the cell-cycle in WHCO1 cells 
treated with 200. To determine whether 200 induced cell-cycle arrest in WHCO1 cells, cells were 
treated with 200 at 2 × 24-hour IC50 concentration (40 μM), and FACS analysis was performed 0, 6, 







































12 hours 24 hours 
Figure 3.6. Cell-cycle profiles of WHCO1 cells treated with 200 in a time-dependent manner. 
WHCO1 cells were treated with 2 × 24-hour IC50 of 200 (40 μM) for 0, 6, 12 and 24 hours for FACS 
analysis. A time-dependent increase in G2/M cell-cycle arrest was observed, with a concurrent 
decrease in the G1- and S-populations. 
 
3.2.5. Apoptosis (histone dissociation) 
During apoptosis, the DNA within cells become fragmented to produce histone-associated 
DNA fragments of ~ 200 base pairs, which are released into the cytoplasm, providing a 
method for apoptosis detection and quantification. Roche has developed an ELISA-based 
assay that detects histone-associated DNA fragments in the cytoplasm after treatment, which 
can be used as a measure of apoptosis. WHCO1 cells were treated with t-PMB or 200 for 24 
hours and then lysed, where after the lysate was transferred to a streptavidin-coated multi-
plate. Thereafter, a mixture of anti-histone-biotin (which binds to the streptavidin multi-plate 
through biotinylation) and anti-DNA-POD was added to the multi-plate to detect cytoplasmic 
histone-associated DNA fragments. Unbound components were removed through a wash-








using the ABTS substrate (see Materials and Methods section). Experiments were performed 
in triplicate and significance was determined using the student t-test. 
The positive control used in the assay was a DNA-histone complex provided with the 
Roche® Cell Death Detection ELISA
PLUS 
kit, and the negative control was cells in 0.1 % 
DMSO in media. Apoptosis was observed in WHCO1 cells treated with IC50 (p-value = 0.02) 
and 2 × IC50 (p-value = 0.02) of t-PMB for 24 hours, although it was not observed in 
WHCO1 cells treated with t-PMB ½ IC50 or   ⁄  IC50 (Figure 3.7). This finding supports the 
morphology changes shown in Figure 3.9, where WHCO1 cells treated with t-PMB at 2 × 
IC50 and IC50 appeared shrivelled indicative of apoptosis, but WHCO1 cells treated with t-
PMB at ½ IC50 and   ⁄  IC50 had similar morphologies to the untreated control cells. 
 
Figure 3.7. Apoptosis in WHCO1 cells treated with t-PMB in a dose-dependent manner. A 
histone-associated DNA fragmentation assay was performed to quantitate apoptosis in WHCO1 cells 
treated with t-PMB at 2 × IC50, IC50, ½ IC50 and   ⁄  IC50 for 24 hours. The negative control was cells 
treated with 0.1 % DMSO in media alone, and the positive control was a DNA-histone-complex, 
which was provided with the kit. The data are indicated with ± SD and significant changes are 
highlighted (* indicates p-value < 0.05). 
 
WHCO1 cells treated with 200 were also found to display increased levels of apoptosis in 
cells treated with 2 × IC50 (p-value = 0.01), IC50 (p-value = 0.003) and ½ IC50 (p-value = 
0.001), with no significant effect at   ⁄  IC50 (Figure 3.8). Furthermore, morphology images 
indicated in Figure 3.9 show that cells treated with at least 10 μM 200 have shrivelled and 
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Figure 3.8. Apoptosis in WHCO1 cells treated with 200 in a dose-dependent manner. A histone-
associated DNA fragmentation assay was performed to quantitate apoptosis in WHCO1 cells treated 
with 200 at 2 × IC50, IC50, ½ IC50 and   ⁄  IC50 for 24 hours. The negative control was cells treated with 
0.1 % DMSO in media alone and the positive control was a DNA-histone-complex, which was 
provided with the kit. The data are indicated with ± SD, and significant changes are highlighted (* 
indicates p-value < 0.05, *** indicates a p-value < 0.005). 
 
3.2.6. ROS production 
To determine whether ROS production is related to the ability of disulfides and thiosulfonates 
to inhibit cancer cell proliferation, ROS production was investigated. To this end, the 2’, 7’ –
dichlorodihydroflourescin diacetate (DCFH-DA) reagent, which fluoresces upon reaction 
with ROS, was used. For the assay, WHCO1 cells were treated with t-PMB or 200 at ½ IC50, 
IC50 or 2 × IC50 concentrations, and subsequent fluorescence was recorded at 0, 1, 2, 3 and 6 
hours post-treatment. The positive control used in the assay was doxorubicin (DOX), which 
is a clinical cancer drug with a mechanism that involves production of ROS. 
As seen in Figure 3.10, treatment with the positive control, 5 μM DOX, resulted in a 
significant increase in ROS levels for up to 6-hours. The levels of ROS in the untreated 
sample also appear to increase with time, which may be a result of more cells being present 
due to cell-proliferation, hence more endogenous ROS being detected. Furthermore, a time- 
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Figure 3.9. Phase contrast images of morphological changes in WHCO1 cells treated with either 
t-PMB or 200 for 24 hours.  The phase contrast images represent WHCO1 cells treated with t-PMB 
or 200 at 2 × IC50, IC50, ½ IC50 and   ⁄  IC50 for 24 hours. Apoptosis induction was detected using the 
Roche® Cell Death Detection ELISAPLUS kit.  
 
Neither a dose- nor a time- dependent increase in ROS levels were detected for WHCO1 cells 
treated with 200 when compared to media alone, although treatment with 200 at 2 × IC50 (40 
μM) at the 1-hour time-point was found to be significant (Figure 3.11). It should be noted that 




IC50, which raises the question as to whether ROS production is important for the anti-
proliferative activity of garlic OSC.  
 
Figure 3.10. ROS production in WHCO1 cells treated with t-PMB in a dose- and time-
dependent manner. WHCO1 cells were treated with t-PMB at 2 × IC50, IC50 and ½ IC50 for 0, 1, 2, 3 
and 6 hours. Control cells were treated with media alone or 0.1 % DMSO in media. As a positive 
control, WHCO1 cells were treated with 5 μM doxorubicin (DOX). The experiment was performed in 
triplicate and the data are indicated with ± SD. 
 
 
Figure 3.11. ROS production in WHCO1 cells treated with 200 in a dose- and time-dependent 
manner. WHCO1 were cells treated with 200 at 2 × IC50, IC50 and ½ IC50 for 0, 1, 2, 3 and 6 hours. 
Control cells were treated with media alone or 0.1 % DMSO in media. As a positive control, WHCO1 
cells were treated with 5 μM doxorubicin (DOX). The experiment was performed in triplicate and the 
data are indicated with ± SD. 
 
3.2.7. ROS inhibition 
To determine whether ROS production is important in the anti-proliferative activity of t-
PMB and 200, WHCO1 cells were pre-treated for 1 hour with known ROS inhibitors, and 
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Firstly, ROS scavengers were tested for their ability to scavenge OSC-induced ROS 
production in WHCO1 cells treated with t-PMB or 200. The ROS scavengers, whose 
concentrations were based on literature, were chosen to be N-acetyl-L-cysteine (NAC) 
(Dirsch et al. 1998), L-ascorbic acid (ascorbate) (Das et al. 2007) and TROLOX (Kelkel et al. 
2012).  
Compound t-PMB; ROS inhibitors and ROS production: In agreement with previous 
findings, WHCO1 cells treated with t-PMB for 3 hours at the IC50 concentration generated a 
1.5-fold increase in ROS relative to the untreated controls (Figure 3.12). The levels of ROS 
production by t-PMB (p-value = 0.003) were found to be similar to the levels produced by 
DOX (p-value = 0.008). Treatment with any of the 3 ROS inhibitors alone resulted in a 
significant decrease in ROS levels to below baseline levels, indicative of scavengers 
removing endogenous ROS from the WHCO1 cells. Treating WHCO1 cells with t-PMB in 
combination with ROS scavengers; NAC (p-value = 8 × 10
-5
), ascorbate (p-value = 8 × 10
-5
) 
and TROLOX (p-value = 4 × 10
-5
) significantly decreased ROS levels compared to the t-
PMB-treated sample, indicating that all ROS inhibitors effectively scavenged t-PMB-
induced ROS production.  
 
 
Figure 3.12. ROS inhibition assay in t-PMB-treated cells. To confirm whether ROS scavengers; 
NAC, ascorbate or TROLOX scavenge t-PMB-induced ROS production, WHCO1 cells were treated 
with either 25 μM t-PMB alone or 25 μM t-PMB in combination with ROS scavengers; NAC, 
ascorbate or TROLOX for 3 hours. The data was collected in triplicate and is displayed as a mean ± 
SD. Significant changes are highlighted (** indicates p-value < 0.01, *** indicates p-value < 0.005, 
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Compound t-PMB; ROS inhibitors and cell proliferation: To determine whether ROS 
production is important for the anti-proliferative activity of t-PMB, WHCO1 cells were 
treated with the IC50 concentration of t-PMB in the presence of ROS scavengers; 7.5 mM 
NAC, 50 μM ascorbate or 12.5 μM TROLOX, and the viability was assayed using the MTT 
assay. As expected (Figure 3.13), treating WHCO1 cells with t-PMB at its IC50 concentration 
resulted in a 50 % reduction in cell viability (p-value = 0.01). Treating WHCO1 cells with the 
inhibitors alone was found to have no effect on cell viability. When treating WHCO1 cells 
with t-PMB in the presence of the ROS scavengers, different effects on cell viability were 
observed. WHCO1 cells treated with t-PMB in the presence of NAC resulted in cell viability 
levels similar to that of the untreated control, indicating that pre-treatment with NAC 
prevented t-PMB-induced reduction in cell viability. On the other hand, treatment with t-
PMB in the presence of ascorbate (p-value = 0.01) or TROLOX (p-value = 0.01) resulted in a 
significant reduction in cell viability, similar to the viability levels observed for WHCO1 
cells treated with t-PMB alone, indicating that although ascorbate and TROLOX reduce ROS 
levels in t-PMB-treated cells, they are ineffective at inhibiting the t-PMB-induced reduction 
in cell viability.  
 
  
Figure 3.13. Cell viability (MTT) of WHCO1 cells treated with t-PMB in the presence of ROS 
scavengers. WHCO1 cells were treated with either 25 μM t-PMB alone or 25 μM t-PMB in 
combination with ROS inhibitors; NAC, ascorbate or TROLOX for 24 hours, and cell viability was 
quantified using the MTT assay. The data was collected in triplicate, and displayed as a mean ± SD 
with significant changes highlighted (* indicates p-value < 0.05, *** indicates p-value < 0.005; NS 
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These data seem to imply that NAC is capable of reversing the anti-proliferative effects of t-
PMB, however, the ROS scavengers, ascorbate and TROLOX are ineffective. The 
implication of these results will be discussed in greater detail in the Discussion section. 
Compound 200; ROS inhibitors and ROS production: As observed before, DOX treatment 
for 3 hours caused a significant (p-value = 0.003) increase in the levels of ROS in WHCO1 
cells, and treatment with any of the three ROS inhibitors alone resulted in a significant 
decrease in ROS levels of untreated WHCO1 cells to below baseline levels, indicative of 
scavengers removing endogenous ROS from the WHCO1 cells. Treatment with 200 at IC50 
concentration for 3 hours resulted in no significant increase in ROS (Figure 3.14). It was 
therefore expected that co-treatment of 200 with the ROS inhibitors should have no effect on 
cell viability, as ROS was not generated by 200.  
 
 
Figure 3.14. ROS inhibition assay in 200-treated cells. To confirm whether ROS scavengers; NAC, 
ascorbate or TROLOX scavenge 200-induced ROS production, WHCO1 cells were treated with either 
20 μM 200 alone or 20 μM 200 in combination with ROS scavengers; 7.5 mM NAC, 50 μM ascorbate 
or 12.5 μM TROLOX for 3 hours. The data was collected in triplicate and is displayed as a mean ± 
SD. Significant changes are highlighted (*** indicates p-value < 0.005). 
 
Compound 200; ROS inhibitors and cell proliferation: In the MTT assay (Figure 3.15), we 
observed that treating WHCO1 cells with 200 at its IC50 concentration resulted in the 
expected 50 % decrease in cell viability. Furthermore, pre-treating the cells with NAC, 
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indicating that treatment with the ROS scavengers does not change cell viability. However, 
treating WHCO1 cells with 200 and NAC (p-value = 0.02) resulted in cell-viability similar to 
that of the untreated control, even though ROS production was clearly not observed (Figure 
3.14). This result suggests that NAC may not be restoring cell-viability through its ROS 
scavenging properties, but may be interacting directly with the compound. We hypothesised 
that NAC, a cysteine-derivative with a thiol group, may be restoring WHCO1 cell viability by 
directly reacting with the disulfide and thiosulfonate functional groups of 200 and t-PMB, 
thereby lowering the concentrations of the OSC within the cell, and preventing the OSC from 
inhibiting WHCO1 cell viability through a mechanism independent of ROS. This is 
supported as treatment of WHCO1 cells with 200 in the presence of ascorbate and TROLOX 
did not restore cell viability, even though both scavengers reduce ROS levels in WHCO1 
(Figure 3.14).  
 
 
Figure 3.15. Cell viability (MTT) of WHCO1 cells treated with 200 in the presence of ROS 
scavengers. WHCO1 cells were treated with either 20 μM 200 alone or 20 μM 200 in combination 
with ROS scavengers; NAC, ascorbate or TROLOX for 24 hours and cell viability was quantified 
using the MTT assay. The data was collected in triplicate and displayed as a mean ± SD with 
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3.2.8. Reaction between NAC and t-PMB 
Although NAC, TROLOX and ascorbate scavenged t-PMB-induced ROS production, only 
pre-treatment with NAC restored the cell viability of WHCO1 cells treated with t-PMB. 
Furthermore, although ROS production was not detected in WHCO1 cells treated with IC50 
concentrations of 200 for 3 hours, pre-treatment with NAC also restored cell viability within 
these 200-treated cells. We therefore hypothesised that pre-treatment with NAC may have 
restored WHCO1 viability through a mechanism other than ROS scavenging. We proposed 
that NAC, a cysteine-derivative with an acetyl group attached at the nitrogen, may be reacting 
with t-PMB and 200 through mixed disulfide bond formation between the disulfide 
functional group in the OSC and the thiol group in NAC, thereby lowering the concentration 
of the OSC within the cell. To determine whether t-PMB and NAC are able react, an in vitro 
reaction between t-PMB and NAC was performed by Mr. Daniel Kusza at the Chemistry 
Department of UCT, in tetrahydrafuran (THF) at room temperature overnight. The reaction 
product was isolated and characterised by NMR (Figure 3.17), and was shown to be N-acetyl 
cysteine methoxybenzyl disulfide (Figure 3.16), a mixed disulfide product of t-PMB and 
NAC. This result supports the hypothesis that NAC may reacting directly with t-PMB or 200 
in the WHCO1 cells to form a mixed disulfide product, thereby preventing t-PMB- or 200- 
from inhibiting WHCO1 cell growth. 
 
 
Figure 3.16. Chemical reaction between NAC and t-PMB. The schematic represents the reaction 
between t-PMB and NAC, resulting in the product, N-acetyl cysteine methoxybenzyl disulfide, which 
may result in lower t-PMB concentrations within cells, preventing t-PMB from inducing its anti-
cancer effects. 
































































Figure 3.17. NMR profile for N-acetyl cysteine methoxybenzyl disulfide. To determine whether 
NAC and t-PMB react, an in vitro chemical reaction between NAC and t-PMB was carried out in 
THF at room temperature. The product of the reaction was purified by silica gel chromatography and 
characterised through nuclear magnetic resonance (NMR), and found to be N-acetyl cysteine 
methoxybenzyl disulfide, a mixed-disulfide product of t-PMB and NAC. Characterisation of each 
hydrogen atom is colour-coded and numbered, with the representative hydrogen atom numbered in 
the N-acetyl cysteine methoxybenzyl disulfide chemical structure. Each peak representing the solvent, 
























One compound from each of the disulfide and thiosulfonate compound classes were chosen 
for further mechanistic evaluation against WHCO1 cell death. Compounds t-PMB and 200 
were selected based on their low IC50-values, and because large amounts of the synthesised 
material was available.  
It was evident that a degree of selectivity was observed for cancer cells over non-cancer cells 
when treating with t-PMB and 200. Compound t-PMB was found to be 2.5-fold selective, 
and 200 was 10-fold selective, to the WHCO1 cancer cell-line over the Het1A non-cancer 
cell-line. The lower IC50, and greater selectivity to cancer cells over non-cancer cells, 
suggests that 200 may be a better candidate as a chemotherapeutic in terms of reduced 
cytotoxicity. The 48-hour IC50 of t-PMB and 200 against the A375 human melanoma was 
found to be 2.27 μM and 3.17 μM respectively, indicating that both compounds are more 
active against the A375 cell growth than WHCO1 cell growth, suggesting that the compounds 
may be selective in their anti-cancer activity.  
The MTT assay, which is a measure of cell viability, is commonly used as an indirect 
measure for cell-proliferation. To confirm the anti-proliferative effects of t-PMB and 200, the 
BrdU assay was performed on WHCO1 treated with either compound at 2 × IC50, which 
reduced cell proliferation levels similar to that of background levels. This result is in strong 
agreement with the MTT assay, and furthermore suggests that the MTT results for the 
remaining data series are reliable. Phase contrast images of morphological changes in 
WHCO1 cells treated with 2 × 48 hour IC50 of t-PMB (30 μM) or 200 (20 μM) showed that 
most cells had lost their regular morphology and shrivelled, indicative of apoptosis. 
Garlic OSC’s, to include;  ajoene (Li et al. 2002; Dirsch et al. 2002), DATS (Kim et al. 2007; 
Xiao et al. 2004), DADS (Filomeni et al. 2003; Das et al. 2007; Yang et al. 2009), and allicin 
(Kim et al. 2008), have been reported to induce apoptosis in a number of cancer cell-lines. 
Both t-PMB and 200, like garlic-derived organosulfur compounds, appeared to induce a 
dose-dependent increase in the levels apoptosis, although the measured levels of apoptosis for 
each compound was found to be the same when treating with IC50 and 2 × IC50 
concentrations. An explanation for this may be that treating cells with the compounds at 
twice their respective 24-hour IC50’s for 24 hours may result in most of the cells dying, 




environment, and enter the media environment, where it may become unstable and degrade, 
becoming undetectable to the histone anti-body. We observed that the apoptosis levels in 
WHCO1 cells treated with t-PMB at ½ IC50 were similar to background levels, however the 
levels of apoptosis were elevated in cells treated with 200 at ½ IC50, which seems to imply 
that 200 is more effective at inducing apoptosis than t-PMB.  
FACS analysis in WHCO1 cells treated with 2 × 24-hour IC50 of t-PMB or 200 showed a 
time-dependent increase in G2/M cell-cycle arrest, with a concurrent decrease in the number 
of cells in the G1- and S-phase of the cell-cycle, although the G2/M arrest for 200 peaked 
earlier than for t-PMB, which implies that the kinetics of cell-cycle arrest by 200 may be 
more rapid compared to t-PMB. Although G2/M cell-cycle arrest has been reported for 
garlic-derived OSCs;  ajoene (Li et al. 2002; Dirsch et al. 2002), DATS (Kim et al. 2007; 
Xiao et al. 2004), DADS (Filomeni et al. 2003; Das et al. 2007; Yang et al. 2009), and allicin 
(Kim et al. 2008), this is the first time it is reported for a thiosulfonate compound. 
The ROS assay showed a significant dose- and time- dependent increase in the levels of ROS 
produced in WHCO1 cells treated with t-PMB, but not for 200, which only showed a 
significant increase in ROS levels when treating with 2 × IC50 (40 μM) for 1 hour. It has 
previously been reported that treating cancer cells with garlic OSCs, to include; ajoene 
(Dirsch et al. 1998), DATS (Kim et al. 2007), DADS (Das et al. 2007; Kwon et al. 2002; Wu 
et al. 2005; Filomeni et al. 2003) and DAS (Das et al. 2007), result in increased ROS 
productions, and although thiosulfonates are not reported to be found in garlic, t-PMB 
appears to also induce increased levels of ROS in cancer cells, similar to that of garlic-
derived OSC. 
To determine whether ROS production is important for the anti-cancer mechanism of OSC, 
WHCO1 cells were treated with t-PMB or 200 in combination with ROS scavengers; NAC, 
ascorbate and TROLOX. It was observed that WHCO1 cells treated with t-PMB in 
combination with either ROS scavenger showed a significant reduction in ROS levels. 
Although, pre-treatment with NAC, but not ascorbate or TROLOX, resulted in restored 
WHCO1 cell viability, and so we hypothesised that NAC, a cysteine derivative with a thiol 
group, may have reacted with t-PMB and 200 to form a mixed-disulfide product, thereby 
lowering the concentration of t-PMB and 200 in the cell. To determine whether t-PMB and 
NAC are able to react in vitro, the two compounds were combined in THF at room 




characterised to be N-acetyl cysteine methoxybenzyl disulfide, a mixed disulfide product of t-
PMB and NAC. It is possible that the reaction between t-PMB and NAC may have taken 
place within the WHCO1 cells, thereby lowering the concentration of t-PMB in the cell and 
preventing t-PMB from inhibiting WHCO1 cell viability. This result may provide a rationale 
as to why pre-treatment with NAC, but not ascorbate and TROLOX, resulted in viability 
levels similar to that of untreated cells. Furthermore, although ROS production was not 
observed in WHCO1 cells treated with the IC50 concentration of 200, pre-treatment with 
NAC still restored cell viability. This result supports our proposal that NAC may not be 
restoring cell viability in t-PMB-treated through its ROS scavenging property. A study by 
Kelkel et al. (2012) showed that when DAS4, a garlic-derived OSC, was co-incubated with 
NAC, DAS4 was no longer able to induce β-tubulin polymerisation. It may be that DAS4, 
like t-PMB, formed a mixed disulfide with NAC, preventing the interaction between DAS4 
and β-tubulin. In a study by Dirsch et al. (1998), it was shown that ajoene-induced apoptosis 
in HL-60 leukemia cells was blocked by NAC, but not by catalase. It may be that ajoene, like 
t-PMB, formed a mixed disulfide product with NAC, thereby lowering the concentrations of 
ajoene within the cell.  
These results indicate that although treatment of WHCO1 cells with t-PMB resulted in 
increased levels of ROS production, ROS production did not appear to form part of the anti-
cancer mechanism in WHCO1 leading to cancer cell-death; a finding which contradicts the 
results by Das et al. (2007), who observed that when DADS-treated T98G and U87MG 
glioblastoma cells are pre-treated with ascorbate, a decrease in apoptosis levels was observed. 
The reason as to why Das et al. (2007) observed the importance of ROS production, and we 
did not, may be because the anti-cancer mechanism through ROS production may be cancer 
cell-line specific or analogue specific or possibly by some other explanation.  
Although t-PMB contains a thiosulfonate functional group, a compound class not reported to 
be found in garlic, it appeares to bring about its anti-cancer effects through mechanisms that 
have been described for garlic-derived OSCs, by inducing cell-cycle arrest and apoptosis. 
Furthermore, even though the DADS analogue, 200, has varied side groups, it still displayed 
anti-proliferative activity, inducing its anti-cancer mechanism through G2/M cell cycle arrest 
and apoptosis, supporting the hypothesis that the disulfide functional group may be important 
for the anti-cancer activity of OSC. There is much evidence in the literature to support a ROS 
generating mechanism for garlic OSC, and much of this evidence is supported by using the 




induce its anti-cancer mechanism through ROS production, and that NAC is a poor choice of 




































Previous in vivo studies on garlic-derived OSC have shown that they are able to reduce 
tumour sizes in mouse and rat models. It has been observed that mice with human colon 
cancer xenografts showed a significant reduction in tumour size when treated with 0.5 mg 
DADS (Sundaram & Milner 1996b), 6 mg/kg DATS (Hosono et al. 2005) or 80 ppm S-
methylmethane thiosulfonate (S-MMTS) via IP injection (Kawamori et al. 1995; Reddy et al. 
1999). It has also been reported that 25 mg/kg ajoene reduced melanoma size by 3-fold in 
mice, when compared to the untreated control (Tilli et al. 2003), and furthermore, topical 
application of 250 μg ajoene reduced the size of chemically-induced skin tumours in rodents 
and humans (Nishikawa et al. 2002). Application of ajoene to human patients with basal cell 
skin carcinoma also reduced tumour sizes in 81 % of patients (Taylor et al. 2006). 
Based on the literature evidence for in vivo anti-cancer activity of garlic-derived OSC, and 
after observing the promising in vitro anti-cancer activity of t-PMB and 200, together with 
the low cytotoxicity profiles, we decided to investigate whether the compounds showed any 
in vivo anti-cancer activity against both WHCO1 oesophageal cancer and A375 human 












4.2.1. Nude mice with A375 xenografts treated intraperitonealy with 200 
Since both t-PMB and 200 were found to have superior activity against the A375 human 
melanoma cells over the WHCO1 oesophageal cancer cells in culture, we decided to test 
whether t-PMB and 200 were active at inhibiting the growth of an A375 xenograft in nude 
mice. For the experiment, tumour sizes were measured with callipers, and the tumour volume 
was determined using the formula:                                
             
 
.  
Eighteen nude mice were randomised into two groups (N = 9) and inoculated with 5 × 10
6
 
A375 cells in the right flank, and then immediately given the first intraperitoneal (IP) 
injection with 50 mg/kg 200 (solubilised in 50 % polyethylene glycol (PEG), 10 % DMSO 
and 2.5 % chondroitin, a solubilisation formulation that was developed by our collaborator, 
Dr. Andriy Garfov, in Finland). The untreated control group was IP injected with the vehicle 
alone (50 % PEG, 10 % DMSO and 2.5 % chondroitin). For the first 4 days, mice were 
treated with 50 mg/kg 200 daily. Following the death of 4 mice in the treated group, 
treatment was stopped for 3 days, where after the dose was decreased to 25 mg/kg 200 to the 
remaining 5 mice, administered only every second day via IP injection.  The remaining 5 
mice treated with 200 every second day appeared normal and gained weight (Figure 4.3). 
Furthermore, histopathalogical analysis of organs in the 200-treated mice killed on day 24 
showed no toxicity to the liver, adrenal glands, kidneys, lymphocytes and heart (Figure 4.4). 
It can therefore be concluded that a dose of 25 mg/kg 200 every second day is acceptable, and 
not toxic. 
As seen in Figure 4.1, the remaining 5 nude mice treated with 200 every second day showed 
a significant decrease in tumour size at 15 days (p-value = 0.01) and 18 days (p-value = 0.01) 
post-treatment; however after 18 days, when the tumours began to grow rapidly, this 
significance was lost. On day 24, the mice were euthanized and the tumours were harvested, 
with the exception of one tumour which turned necrotic in an untreated mouse. The tumours 
were weighed to reveal no significant decrease in tumour weight between the untreated and 
200-treated groups (Figure 4.2), which is in agreement with calliper measurements on day 24 
(Figure 4.1) at the end of the experiment.  
Whole blood analysis was performed at IDEXX laboratories on blood isolated from a 200-




haemoglobin levels, white cell count, as well as lymphocyte and eosinophil levels; with an 
increase in the percentage of segmented neutrophils and monocytes compared to healthy 
mice.  
 
Figure 4.1. A375 tumour volumes (mm
3
) from nude mice treated by daily IP injection of 200. To 
determine the in vivo anti-cancer activity of 200, nude mice were inoculated with 5 × 10
6
 A375 cells 
in the right flank, and initially treated with 50 mg/kg 200 daily via IP injection, but after observing 
toxicity, the dose was decreased to 25 mg/kg 200 every second day for up to 24 days. The tumour 
volumes were measured twice a week with callipers. The data are indicated with ± SD and significant 




Figure 4.2. A375 tumour weights (mg) from 200-treated and –untreated nude mice removed 
after 24 days. On completion of the in vivo study, the A375 tumours were isolated and weighed, with 
8 mice in the control group and 5 mice in the treated group. No significant (NS) difference in tumour 





















































Figure 4.3. Body weight of 200-treated and -untreated nude mice with A375 xenografts. The 
body weights of 200-treated and -untreated nude mice with A375 xenografts were measured twice a 
week and recorded. We observed no significant difference in the weights recorded for the treated and 
untreated groups for the entire duration of the experiment (24 days). 
 
Histopathalogical findings 
Liver : No specific histopathalogical lesions visible 
Kidney: Mild interstitial congestion. The peri-renal fat tissue at the hilus reveals a blood vessel that 
contains anaplastic appearing round cells and some are attached to the vascular wall. Nuclei 
are large and active and appear hyperchromatic with large nucleoli, and scattered mitoses are 
visible. 
Adrenal gland: No specific histopathological lesions evident 
Lymph node: Diffuse lymphocytic presence without distinction between cortex and medulla in this section. 
Heart: The pericardial mesenteric fat tissue shows multifocal mild lymphocytic presence compatible 
with thymic tissue. Few perivascular lymphocytic aggregates are also visible. 
Lung: Mild alveolar atelectasis multifocally and capillaries show moderate leukostasis and in 
certain areas the alveolar walls also reveal mild thickening due to leukocyte presence. 
 
Figure 4.4. Histopathalogical analysis of nude mice treated with 25 mg/kg 200 via IP injection as 
tested by IDEXX laboratories. To determine whether treatment with 25 mg/kg 200 via IP injection 
every second day had potential side effects to non-cancer tissue in mice; the liver, kidneys, adrenal 































Full blood count 
Test name Test value Units Flag  Range 
Blood count 
Red blood cell count 7.57 × 10
12
/ litre Low 7.90 – 10.0 
Haemoglobin 12.9 g/dl Low 13.9 – 16.7 
Haematocrit  37.0 % - 37.0 – 42.0 
Mean cell volume 48.0 fl - 45.0 – 50.0 
Mean cell haem. cons. 35.0 g/dl - 35.0 – 38.0 
White cell count 2.17 ×10
9
/litre Low 2.90 – 11.9 
Platelet count 900 ×10
9
/litre - 860.0 – 1400  
Differential count 
Segmented neutrophils % 68.0 % High 8.00 – 33.0 
Band neutrophils % 0.00 %  0.00 – 1.00 
Lymphocytes % 23.0 % Low 63.0 – 90.0 
Monocytes % 9.00 % High 0.00 – 5.00 
Eosinophils % 0.00 %  0.00 – 2.00 





/litre  0.17 – 2.47 
Band neutrophils (Abs) 0.00 ×10
9
/litre  0.00 – 0.00 
Lymphocytes (Abs) 0.50 ×10
9
/litre Low 3.36 – 12.7 
Monocytes (Abs) 0.20 ×10
9
/litre  0.08 – 4.52 
Eosinophils (Abs) 0.00 ×10
9
/litre Low 0.11 – 0.39 
Basophils (Abs) 0.00 ×10
9
/litre  0.00 – 0.00 
Figure 4.5. Whole blood cell count on 200-treated nude mice with an A375 xenograft.  In order to 
determine whether treatment with 200 in nude mice affects blood constituent concentrations, a whole 
blood count was performed at the IDEXX laboratories. 
 
4.2.2. Nude mice with WHCO1 xenografts treated intraperitonealy with 200 
Based on the apparent activity of 200 at early time-points in A375 tumour growth, we 
decided to test whether 200 was active against WHCO1 tumour growth. For the experiment, 
16 nude mice were randomised into two groups (N = 8), and implanted in the right flank with 
5 × 10
6
 WHCO1 oesophageal cancer cells, where the tumour was allowed to establish for the 
first 3 days. Two aggressive mice, one from the treated group and one from the untreated 
group were removed from the study when their tumours were damaged after fighting, leaving 
only 7 mice in each group. Treatment began on day 3, where mice were initially treated with 
20 mg/kg 200 (solubilised in 50 % PEG, 10 % DMSO and 2.5 % chondroitin) via IP injection 
daily, although after observing abdominal swelling in the treated mice with this daily dose, 
the dose was decreased to 10 mg/kg daily (from day 6). Mice in the control group received 
the vehicle alone (solubilised in 50 % PEG, 10 % DMSO and 2.5 % chondroitin). As shown 
in Figure 4.6, the control and treated nude mice displayed similar tumour sizes on day 3 (first 




tumour size in the 200-treated group, although a significant difference in tumour size was 
only seen at 10 days (seventh day of treatment) (p-value = 0.04). Thereafter, the significance 
was lost, as the tumour grew rapidly. At the end of the experiment, the mice were euthanized 
and the tumours harvested, and weighed. In Figure 4.7 we see no significant difference in 
tumour weight between the treated and control groups. Although abdominal swelling 
appeared when administered 20 mg/kg daily, the weight of all of the mice appeared increased 
with time (Figure 4.8), suggesting that the compound was not causing the mice to lose 
weight.  
 
Figure 4.6. WHCO1 tumour volumes (mm
3
) from nude mice treated by daily IP injection of 200. 
To determine the in vivo anti-cancer activity of 200, 16 nude mice were randomised into a treated and 
untreated group (N = 8). The mice were inoculated with 5 × 10
6
 WHCO1 cells in the right flank on 
day 1 and treated via IP injection with 20 mg/kg 200 for the first 6 days (from day 3), thereafter the 
dose was decreased to 10 mg/kg 200 up to 23 days. The tumour volumes were measured twice a week 
with callipers. The data is indicated as a mean ± SD and significant changes are highlighted (* 
indicates p-value < 0.05).  
 
  
Figure 4.7. WHCO1 tumour weights (mg) of 200-treated and untreated nude mice removed 
after 26 days. On completion of the in vivo study, the WHCO1 tumours were isolated and weighed, 
with 7 mice in the treated and 7 mice in the untreated groups. No significant (NS) difference in 
























































Figure 4.8. Body weight of 200-treated and -untreated nude mice with WHCO1 xenografts. The 
body weights of 200-treated and -untreated nude mice with WHCO1 xenografts were measured twice 
a week and recorded. We observe no significant difference in the weights recorded for treated and 
untreated groups for the entire duration of the experiment (26 days). 
 
The blood volume of 4 nude mice treated with 10 mg/kg 200 and 4 control mice treated with 
vehicle alone (50 % PEG, 10 % DMSO and 2.5 % chondroitin) were isolated on the final day 
of the experiment (day 26) 1 hour after the final dose of 200 was administered 
intraperitonealy. The blood plasma samples were analysed for 200 by Ms. Carmen de Kock at 
the Pharmacology department of UCT. A calibration curve was first established for 200 
(Figure 4.9), which ranged from 15.6 to 1000 ng/ml of 200 in mouse plasma. On the day of 
the experiment, quality controls of 200 were prepared in duplicate at two concentrations; 400 
ng/ml (QC1) and 800 ng/ml (QC2). QC1 and QC2 were detected, and found to be 447 ± 21.3 
ng/ml and 859 ± 24.8 ng/ml respectively in mouse plasma. Compound 200, however, was not 
detected in the blood samples from the nude mice treated intraperitonealy with 200. The fact 
that no 200 was observed in the blood 1 hour after IP injection implies that the compound is 
metabolically instable, and may explain the apparent low activity against in vivo tumour 
growth when it is so strongly active in vitro. This result may imply that (1) 200 gets to the 
tumour site and acts very quickly i.e. under an hour, or (2) a secondary metabolite of 200 is 
reducing tumour size in the treated group, or (3) that 200 may be altering tumour growth 
through a secondary effect and is never reaching the tumour to act according to the 
mechanism we have observed in vitro. The combination effects of low metabolic stability and 
































Figure 4.9. Calibration curve for 200. The graph represents a calibration curve used to determine 
the concentration of 200 in blood isolated from nude mice 1-hour after IP injection of 10 mg/kg 200. 
 
4.2.3. Nude mice with A375 xenografts treated intraperitonealy with t-PMB 
For the in vivo study of t-PMB, 20 nude mice were randomised into two groups (N = 10), 
and inoculated with 5 × 10
6
 A375 cells in the right flank, and then immediately given the first 
IP injection of 30 mg/kg t-PMB (solubilised in 50 % PEG, 10 % DMSO and 2.5 % 
chondroitin).  Thereafter, the nude mice were treated with 30 mg/kg t-PMB once a day for up 
to 21 days and untreated control mice received the vehicle alone (50 % PEG, 10 % DMSO 
and 2.5 % chondroitin) (Figure 4.10). Six days after treatment, the smallest mouse in the t-
PMB-treated group died, however we cannot be sure whether the death was caused by the 
compound. A significant decrease in tumour volume was observed at 9 days (p-value = 0.04), 
13 days (p-value = 0.02) and 16 days (p-value = 0.02) post-treatment, as determined by the 
student t-test. On completion of the study, the mice were euthanized and the tumours were 
isolated and weighed. In Figure 4.11 we see no significant decrease in tumour weight 
between the untreated and t-PMB-treated groups on day 21. Furthermore, when the mice 
were dissected at the end of the experiment, the intestines appeared to have swollen and 
hardened, a sign of inflammation, although mice in both groups appeared to have gained 





Figure 4.10. A375 tumour volumes (mm
3
) from nude mice treated by daily IP injection of t-
PMB. Nude mice were inoculated with 5 × 10
6
 A375 cells on the right flank, and treated with 30 
mg/kg t-PMB once a day for up to 21 days. The tumour volumes were measured twice a week with 
callipers. The data is indicated as an average ± SD and significant changes are highlighted (* indicates 




Figure 4.11. A375 tumour weights (mg) of t-PMB-treated and untreated nude mice removed 
after 21 days. On completion of the in vivo study, the A375 tumours were isolated and weighed, with 
9 mice in the treated and 10 mice in the untreated group. No significant (NS) difference in tumour 
























































Figure 4.12. Body weight of t-PMB-treated and -untreated nude mice with A375 xenografts. The 
body weight of t-PMB-treated and -untreated nude mice with A375 xenografts were measured twice a 
week and recorded. Here we observe that there was no significant difference in the weight of the 











































To investigate whether 200 is active at inhibiting A375 human melanoma xenograft growth 
in nude mice, mice were treated with 50 mg/kg 200 via IP injection daily, which was found to 
be toxic, resulting in 4/9 mice dying in the treatment group. The dose was then decreased to 
25 mg/kg 200 every second day which appeared to have no toxic effects. In support of this, 
histopathalogical analysis of treated mice at the end of the experiment showed no toxicity to 
the liver, kidney, adrenal gland, lymph node, heart or lung in the 200-treated mice, and 
furthermore, the body weights of mice in the treated group increased with time, and were 
similar to that of the controls. Nude mice treated with 200 showed a significant decrease in 
tumour volume up to 18 days, however, when the tumours started to grow more rapidly, the 
significance was lost. Upon isolation of the A375 tumours at the end of the experiment, we 
observed no significant difference in tumour volume or tumour weight between the treated 
and untreated groups, suggeting that 200 may only have been effective within the early stages 
of A375 tumourigenesis. 
The in vivo anti-cancer activity of 200 on WHCO1 oesophageal cancer cells was also 
investigated, where nude mice with WHCO1 xenograft were initially treated with 20 mg/kg 
200 daily. Although, after observing abdominal swelling in some mice treated with 20 mg/kg 
200 daily for the first 6 days, the dose was decreased to a daily treatment of 10 mg/kg 200, 
which appeared to be fine, as we no longer observed abdominal swelling, and the mice 
appeared to be healthy and gained weight. It was evident that although 200 displayed 
promising in vitro anti-cancer activity against WHCO1 cell growth, it did not display 
significant in vivo anti-cancer activity. Throughout the experiment, the average tumour 
volume of treated mice was found to be lower than that of the untreated mice; however a 
significant decrease was only observed day 10, which may have been due to the daily high 
dose of 20 mg/kg 200 for the first 6 days. When the tumours were removed and weighed at 
the end of the experiment, the average tumour weight was lower in the treated than the 
untreated mice; however this difference was not statistically significant. The apparent 
increased activity of 200 in nude mice with the A375 xenograft versus nude mice with the 
WHCO1 xenograft is not too surprising as the IC50 of 200 on the A375 cells was 3.17 μM, 
showing a 3-fold greater selectivity compared to the IC50 of 200 on WHCO1 cells, which was 
9.9 μM. The result therefore suggests that treatment with 200 may be cancer cell-line 
selective. An alternative proposal for increased anti-cancer activity in nude mice with the 




mice with the A375 xenograft, may have resulted in a higher concentration of 200 at the 
tumour site, whereas treating nude mice with a lower concentration of 10 mg/kg 200 every 
day, as was done on nude mice with the WHCO1 xenograft, may have resulted in lower 
concentrations of compound reaching the tumour site. This result is supported by 
pharmacological analysis on blood isolated 1 hour after the nude mice were treated with 10 
mg/kg 200, which showed that 200 was not detected in the blood of the treated mice. In 
support of this, Sundaram & Milner (1996) has shown that nude mice with the human colon 
cancer xenograft, HCT-15, treated with 25 mg/kg DADS via IP injection thrice a week, 
reduced tumour size by 70 % without adverse side-effects (Sundaram Sg & Milner Ja 1996). 
Furthermore, mice with the colon cancer xenograft, COLO205, showed a significant 
reduction in tumour volume when treated with 42 mg/kg DADS via IP injection thrice a week 
(Liao et al, 2007), supporting the proposal that IP injection with a high dose of DADS given 
every second day may be more effective at inhibiting tumour growth, without adverse side-
effects. 
Lawson & Wang (1993) observed that when the garlic OSC, DADS, was incubated in whole 
blood, it had a half-life of 60 minutes, unlike ajoene and allicin which rapidly rearranged to 
form allyl-SH. We therefore suspected that 200, a DADS analogue, would also have had a 
relatively long half-life in whole blood, although, the pharmacokinetic data showed that 200 
was not detected in whole blood from mice 1 hour after IP administration. A possible 
explanation as to why 200 was not detected may be that like ajoene, 200 is an “activated” 
DADS analogue, as the disulfide functional group is flanked by an electron withdrawing 
pyridine group. Ajoene and 200, which theoretically would form mixed disulfide products 
more readily than DADS, may be metabolised more rapidly, resulting lower concentrations of 
compound reaching the tumour site. This result may therefore provide a rationale as to why 
200 was not detected in the blood after treatment.  The observed decrease in tumour size by 
200 may therefore be due to the anti-cancer activity of a metabolite of 200, or that 200 may 
be altering tumour growth slightly through a secondary effect, and is never actually reaching 
the tumour to act according to the mechanism we have observed in vitro. 
When nude mice with the A375 xenograft were treated with 30 mg/kg t-PMB via IP injection 
once a day for up to 21 days, we observed a significant decrease in tumour volume for up to 
16 days of treatment, demonstrating moderate in vivo anti-cancer activity, as was observed 
with 200. Importantly, although a modest decrease in tumour volume and a gain in mouse 




was only evident upon dissection at the end of the experiment, indicating that treating the 
nude mice with 30 mg/kg t-PMB via IP once a day was too high a concentration, and maybe 
treating mice with lower concentrations would decrease this observed effect, although it may 
also remove the anti-cancer effect. In contrast, Kawamori et al. (1995) observed that F344 
rats fed with 80 ppm S-methylmethane thiosulfonate (S-MMTS), a cauliflower-derived 
thiosulfonate compound, significant reduced azoxymethane-induced colon carcinogenesis, 
without adverse side-effects. 
In conclusion, although 200 appeared to be a good candidate as a cancer chemotherapeutic 
based on its in vitro data, with a low IC50 and 10-fold selectivity to WHCO1 cancer cells over 
Het1A non-cancer cells, it did not appear to significantly reduce WHCO1 tumour size in vivo. 
It does although appear to be more effective at inhibiting the growth of the A375 tumour size 
in vivo, which may indicate a certain selectivity to certain cancer types. Furthermore, a high 
dose (25 mg/kg) of 200 given every second say, which appears to have an effect only early in 
tumorigenesis (up to day 18), appeared to more effective than a lower dose (10 mg/kg) given 
daily. In support of this, pharmacokinetic data showed that 200 was not detected in the blood 
of mice 1 hour post-treatment with 10 mg/kg 200. Due to the observed pharmacokinetic data, 
and the observed tumour reduction only within the early stages of tumour development, it is 
not recommended to pursue this line of compounds to drug development. Compound t-PMB 
was found to be effective at decreasing A375 xenograft volume within the early stages of 
tumourigenesisis (up to day 16), however due to the abdominal swelling observed, it is likely 













Investigating protein disulfide isomerase as a potential drug target for OSC 
 
5.1. Introduction 
Protein disulfide isomerise (PDI) is an endoplasmic reticulum (ER)-resident protein whose 
active site cysteine residues are involved in disulfide bond formation and isomerisation 
within newly synthesised proteins (Freedman et al. 1994). We hypothesise that the garlic-
derived organosulfur compounds (OSC) may inhibit the redox and isomerase activities of 
PDI by forming a mixed disulfide with at least one of the PDI active site cysteines, which 
may then result in the inactivation of the enzyme. We decided to test this hypothesis by 
setting up a PDI enzyme assay.  
A known PDI inhibitor, 5’5’-dithio-bis(2-nitrobenzoic acid) (DTNB), is structurally related to 
diallyl disulfide (DADS) in that it contains a disulfide functional group. Although the 
inhibitory mechanism of DTNB on PDI has not been confirmed, it is hypothesised that the 
disulfide functional group of DTNB may form a mixed disulfide with an active site cysteine 
residue of PDI, thereby leading to the inhibition of PDI isomerase and redox activities; a 
hypothesis that we propose for PDI and garlic-related OSC. 
To determine whether PDI is a potential protein target of OSC within cells, we performed 
immunohistochemistry (IHC) with DP, a fluorescent ajoene analogue. We also performed a 













To ensure a strong signal for PDI, we wanted to perform IHC on a cancer cell-line which 
expressed high levels of PDI. Figure 5.1 is a western blot showing the protein levels of PDI 
in 7 different cancer cell-lines when probed with an anti-PDI antibody and detected using a 
secondary antibody linked to horse radish peroxidase (HRP). The extent of 
chemiluminescence of the PDI protein band is normalised for the loading control, 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and is plotted on a histogram (Figure 
5.2). The PDI protein expression levels were found to be highest in the KYSE-180 cell-line, 
an oesophageal cancer cell-line of Japanese origin. This cell-line was thus selected for IHC 
analysis. DP was found to be active at inhibiting the growth of KYSE-180 cells with an IC50 






Figure 5.1. Relative quantities of protein disulfide isomerase (PDI) levels in different cancer cell-
lines. The western blot represents PDI levels in various cancer cell-lines to include HeLa, KYSE-180, 
PC-3, SiHa, A375, MDA-MB-231 and WHCO1 cancer cell-lines. 
 
Figure 5.2. The bar graph represents the relative levels of PDI normalised for GAPDH in various 





























































For IHC, KYSE-180 cells were seeded on a glass cover-slip and treated with DP at its IC50 
concentration (9.1 μM) for 6 hours. Thereafter, the cells were treated with the PDI polyclonal 
primary antibody and the cy-3 fluorescently-tagged secondary anti-body, and mounted on a 
glass slide for viewing under a fluorescence microscope. The KYSE-180 cells were treated 
with DP (9.1 μM), which fluoresces blue, and fluorescent images were taken 6 hours post-
treatment. In Figure 5.3 we see that the PDI signal, which is stained red (A), and DP, which 
fluoresces blue (B), co-localise (C) with each other in the perinuclear region of the KYSE-
180 cells. The phase contrast images of the cells are also shown (D) as well as the co-
localisation signal, which is displayed graphically (E), where pink shows co-localisation 
between DP and PDI. Figure 5.3 E shows a strong pink signal, suggesting that most of the 
DP and PDI co-localised within the KYSE-180 cells, although, a blue signal is also detected, 
suggesting that DP localised to regions of the cells were PDI was not present. This result 
implies that DP may have other protein targets within the KYSE-180 cells. Interestingly, no 
red signal was detected, suggesting that all of the PDI detected co-localised with DP. 
Although IHC may provide evidence that DP and PDI co-localise within the KYSE-180 cells, 
it does not confirm whether the OSC and PDI directly interact, or whether this interaction 
affects PDIs enzymatic activity. We therefore went on to perform a PDI enzyme assay to test 
OSC-induced PDI inhibition.  
Table 5.1. Dose-response-curve and IC50 of DP against the KYSE-180 oesophageal cancer cell-line.  
Compound 
Name  








5.2.2. PDI enzyme assay 
To determine whether analogues of the garlic-derived OSC are able to inhibit PDI enzyme 
activity, a PDI enzyme assay was performed. The assay chosen is based on the oxidative 
renaturation of reduced RNase A by active PDI (Lyles & Gilbert 1991). The renaturation and 
regain of RNase A protein activity was assessed by the ability of this active form to hydrolyse 
KYSE 180 cells treated with DP











IC50 = 9.088 uM





















cytidine 2’,3’-cyclic monophosphate (cCMP). The hydrolysed cCMP product is UV active 
and can be detected spectrophotometrically at 296 nm. All reaction mixtures contained 
glutathione (GSH) and glutathione disulfide (GSSG), as PDI is strongly dependent on the 
presence of these molecules for proper function. 
     
 
Figure 5.3. Co-localisation between PDI and DP in KYSE-180 oesophageal cancer cells. To 
determine whether PDI and ajoene co-localise in cancer cells, KYSE-180 cells were treated with the 
fluorescent ajoene analogue DP, and fluorescence was detected through immunohistochemistry 
(IHC). The image shows that PDI (A) and DP (B) co-localise (C) to the perinuclear region of the 
KYSE-180 cells. The phase contrast image is shown (D) and the co-localisation signal is displayed 
graphically (E).  
 
Each reaction took place in a cuvette at 25 °C, and the reaction was allowed to proceed for 35 
minutes before the absorbance at 296 nm was recorded. For the PDI enzyme assay, three 
control experiments were first performed. These included spectroscopic recordings of (1) 
Native RNase A (NR); (2) Reduced RNase A (RR); and (3) Reduced RNase A in the 
presence of PDI (R-PDI). Thereafter, an inhibitory experiment was performed to test whether 
OSC inhibited PDI enzymatic activity. Here, the inhibitory actions of t-PMB, 200, and DP 
were tested at 20 μM, which is approximately the IC50 concentration for each compound. The 
inhibitory action of DTNB, a known PDI inhibitor with a functional disulfide group, was 
tested at 100 μM, according to concentrations used literature. 





The NR and R-PDI controls were found to have similar absorbance values (Figure 5.4), 
whilst a 4-fold significant (p-value = 0.007) decrease in signal was observed for the RR 
sample, which is expected as the RNase A should re-nature slower in the absence of PDI, 
resulting in a slower rate of cCMP hydrolysis. Furthermore, when compared to the PDI 
control, DTNB, t-PMB, 200, and DP samples displayed significantly decreased absorbance 
values, with p-values being 0.007, 0.03, 0.01 and 7.9 × 10 
-6
 respectively, indicating a 




Figure 5.4. Protein disulfide isomerase (PDI) inhibition enzyme assay. The inhibitory activity of 
DTNB, t-PMB, 200 and DP against bovine PDI was determined using a PDI enzyme assay. The 
assay is based on the oxidative renaturation of RNase A by active PDI. The renaturation and regain of 
RNase A activity by PDI was assessed by its ability to hydrolyse cCMP, whose product can be 
detected spectrophotometrically at 296 nm. Independent triplicate experiments were performed at 25 
°C for 35 minutes. The data are indicated with as a mean ± SD, and significant changes are 
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These results therefore show that DTNB, t-PMB, 200, and DP are able to inhibit PDIs 
enzymatic activity, which could possibly occur through mixed disulfide bond formation 
between the OSC and active site cysteine residues in PDI. Furthermore, even though 100 μM 
DTNB is able to inhibit PDIs enzymatic activity, t-PMB, 200 and DP appear to inhibit PDIs 
enzymatic activity more effectively, and at a much lower concentration (20 μM). This result 
therefore supports our hypothesis that PDI may be a potential target for the OSC-induced 























We propose that OSC may induce their anti-cancer mechanism by forming mixed disulfides 
with cysteine nucleophiles within target proteins, thereby inhibiting protein function, with the 
concurrent expulsion of an anion leaving group. Our previous results have shown a 
correlation between the leaving group stability and the IC50 of various DADS analogues, 
supporting the hypothesis that protein thiolation may be important for OSC-induced cell 
death. Furthermore, we have shown that t-PMB and NAC react to form a mixed disulfide 
product, further supporting the feasibility of protein thiolation as a potential anti-cancer 
mechanism.  
Previous work in our laboratory has shown co-localisation of DP, a fluorescent ajoene 
analogue, to the ER (Kaschula et al, unpublished data). We therefore hypothesised that at 
least one of the OSC protein targets may reside within the ER. PDI, an ER-resident protein 
whose active-site contains cysteine residues (Lyles & Gilbert 1991), was investigated as a 
potential target of OSC in cancer cells.  
To ensure a strong fluorescence signal for the IHC assay, we performed a western blot on 
various cancer cell-lines to determine relative PDI levels. After having observed that the 
KYSE-180 oesophageal cancer cell-line had the highest levels of PDI in the series, the cell-
line was used for IHC. Although we observed that most of the DP co-localised with PDI, DP 
also appeared to have localised to other regions of the cell where PDI was not present. This 
implies that DP may have other cellular protein targets, like glutathione reductase (Krauth-
Siegel et al. 1996) or β-tubulin (Hosono et al. 2005), which are proposed targets of garlic 
OSC. Interestingly, we observed no red signal apart from the blue signal, which indicates that 
all PDI detected had co-localised with DP. Although this result provides evidence that DP 
and PDI co-localise within the KYSE-180 cells, it does not confirm whether the OSC and 
PDI directly interact, or whether this interaction affects PDIs enzymatic activity. It was 
therefore important to test whether OSC were actually able to inhibit PDIs enzymatic activity. 
To determine whether OSC inhibit the enzymatic activity of PDI, a PDI enzyme assay was 
performed. For the enzyme assay, we tested the inhibitory effects of t-PMB, 200, DP at 20 
μM (approximately IC50), as well as DTNB at 100 μM. We observed that NR and R-PDI had 
similar absorbance values, whilst there was a 4-fold significant decrease in signal for the RR 
sample, which is expected as the RNase A would re-nature slower in the absence of the PDI 




DTNB, t-PMB, 200, and DP samples displayed significantly decreased absorbance values, 
suggesting a decrease rate of RNase A re-naturation, and subsequent cCMP hydrolysis. These 
results therefore provide strong evidence that garlic-related disulfides may inhibit PDIs 
enzyme activity in vitro, although whether this observed PDI inhibition occurs in the cancer 
cell will warrant further investigation. 
For the first time, we observed that OSC are able to co-localise with, and inhibit PDI enzyme 
activity. Previous work in our laboratory has shown that when WHCO1 cells were treated 
with E/Z-4l, an ajoene analogue 12 times more active than the parent compound, an increase 
in the mRNA levels of CHOP, a protein marker of ER stress, were observed (Kaschula et al, 
unpublished data). With these results we hypothesise that should treatment with OSC result in 
PDI enzyme inhibition within cancer cells, the accumulation of unfolded proteins may lead to 
























Garlic-derived organosulfur compounds (OSCs), to include E/Z ajoene, diallyl trisulfide 
(DATS), diallyl disulfide (DADS), diallyl sulfide (DAS) and allicin have all been shown to 
be active at inhibiting tumour cell proliferation both in vitro and in vivo. In our study, we 
propose that the disulfide or polysulfide functional group of the OSC may react with a 
cysteine nucleophile from a protein, to result in the formation of an alkylated protein product 
with altered function, and the concurrent expulsion of an anion leaving group. The chemical 
reactions between OSC and cysteine nucleophiles of proteins are governed by both 
thermodynamic and kinetic parameters, where the thermodynamics are largely driven by the 
stability of the products, which in our case is the expelled anion leaving group. Factors which 
increase the stability of an anion include degree of conjugation, resonance and number of 
electronegative atoms. Incoming nucleophilic attack by a cysteine thiol is kinetically 
controlled, and dependent on the accessibility of the cysteine nucleophile to the disulfide of 
the OSC. In our study, we determined the 48-hour anti-proliferation-IC50 of 15 organosulfur 
analogues, which included 10 DADS analogues, 1 allicin analogue and 4 thiosulfonate 
compounds, a compound class not reported to be found in garlic. Our results show that the 
DADS analogues displayed varying degrees of anti-cancer activity against WHCO1 
oesophageal cancer cell proliferation, ranging from 5 μM to inactive (> 200 μM). We 
observed that a compound with a more stable leaving group produced a more active 
compound, and furthermore that steric hindrance over the disulfide functional group removed 
anti-cancer activity, regardless of leaving group stability.  
The stability of the leaving group anion was also assessed by determining its pKa-value, 
where a leaving group with a lower pKa-value is considered to be more stable. Compounds 2, 
21, 200 and 30 were all used to determine the relationship between leaving group stability 
and IC50 in the DADS series, where the common R1-group was a fixed propyl, and therefore 
the reactivity was dependent solely on the nature of the R2-leaving group. Our results showed 
a positive correlation between compound IC50 and the leaving group pKa, with an R
2
-value of 
0.88. Although compounds 2 and 8 are structurally similar, the IC50 of 8 was significantly 




hindrance over the disulfide pharmacophore. Allicin-16, a thiosulfinate, is structurally similar 
to 16, a DADS analogue. Although, the IC50 of Allicin-16 (71 µM) is lower than 16 (> 200 
µM). The higher activity of allicin-16 may be due to the presence of the oxygen on its sulfur, 
which may enhance its anti-cancer activity by making the thiosulfonate more labile to 
thiolation. This is likely because the oxygen atom on the sulfur has electron-withdrawing 
properties, resulting in a better leaving group. The water-soluble compound, 92, was found to 
be inactive, which was not too surprising as the water-soluble DADS analogue, S-
allylmercaptocysteine (SAMC), is reported to be 3-fold less active than DADS (Kwon et al. 
2002; Danhua Xiao et al. 2005; Yang et al. 2009). This result implies that a degree of 
lipophilicity is required for anti-cancer activity. Since the leaving group in the thiosulfonate 
compound class was the same in all cases, it may offer an explanation as to why these 
compounds had similar IC50’s in the range of 15 μM.  These results suggest that the reaction 
between a disulfide and a cysteine nucleophile of a potential protein target may be 
thermodynamically and kinetically controlled. It furthermore supports the hypothesis that the 
disulfide functional group is important for the anti-cancer activity of OSC, and that the side-
groups appear to play an important modulatory role.  
To investigate the mechanism of action of disulfides and thiosulfonate compounds in 
WHCO1 oesophageal cancer cells, 200, a DADS analogue, and t-PMB, a thiosulfonate 
compound, were selected for further evaluation. The anti-cancer mechanism was assessed by 
observing morphological changes in treated cells, assaying whether the compounds generate 
reactive oxygen species (ROS) and testing whether they induce cell-cycle arrest and 
apoptosis. 
Although the MTT assay measures cell viability, it is also a good indirect measure of cell-
proliferation. The BrdU assay, which directly measures cell proliferation, confirmed that 2 × 
IC50 concentration of t-PMB and 200 were able to reduce cell proliferation down to 
background levels. Furthermore, morphology images of WHCO1 cells treated with 2 × IC50 
concentrations of t-PMB and 200 showed that cells appeared rounded, indicative of 
apoptosis. In literature, it is reported that ajoene (Li et al. 2002; Dirsch et al. 2002), DATS 
(Kim et al. 2007; Xiao et al. 2004), DADS (Filomeni et al. 2003; Das et al. 2007; Yang et al. 
2009) and allicin (Kim et al. 2008) induce apoptosis in cancer cells, so we went on to 
investigate whether the OSC in our study also induce apoptosis in WHCO1 cells. Apoptosis, 
determined through the detection of histone-associated DNA fragments, was detected in 




inducing apoptosis than t-PMB, implying that 200 may be a better drug candidate than t-
PMB due to lower IC50 and increased levels of apoptosis in WHCO1 cells. 
In the literature, there is evidence to suggest that ajoene (Dirsch et al. 1998), DATS (Kim et 
al. 2007), DADS (Das et al. 2007; Kwon et al. 2002; Wu et al. 2005; Filomeni et al. 2003) 
and DAS (Das et al. 2007) may mediate their anti-cancer effects through increased ROS 
production, although Kelkel et al. (2012) did not find increased levels of ROS in the U937 
human histiocytic lymphoma cells treated with diallyl tetrasulfide (DAS4), another garlic-
derived OSC. We have already identified the importance of thiolation based on anion leaving 
group stability (Figure 6.1, Scenario 2), so we decided to further investigate whether ROS 
production is also important. It is possible that ROS may be generated as a result of the 
expelled leaving group thiol which may undergo homolytic cleavage to produce a thiyl 
radical. The thiyl radical, which is very unstable, may react with free oxygen in the cell to 
produce superoxide, which in turn is a precursor to ROS (Figure 6.1, Scenario 1). It is 
predicted that a leaving group with a high pKa may form a less stable thiyl radical, which 
would more readily react with free oxygen, and produce higher levels of ROS. In support of 
this hypothesis, we observed that t-PMB (pKa = 6.82), produced a significant amount of ROS 
in a time- and dose-dependent manner, whereas 200 (pKa = 2.71) produced very little ROS. 
 
 
Figure 6.1 Possible model for OSC-induced cancer cell-death in WHCO1 cells, which was found not 
to occur through increased levels of ROS (Scenario 1), although protein thiolation by OSC was found 





To determine whether ROS production is important in the anti-cancer mechanism of OSC, 
WHCO1 cells were treated with the IC50 concentrations of t-PMB or 200 following pre-
treatment with the ROS scavengers; NAC, ascorbate or TROLOX, which resulted in 
decreased levels of ROS to below that of the untreated control. WHCO1 cells treated with t-
PMB or 200 in the presence of NAC resulted in cell-viability levels similar to that of the 
untreated control, indicating that pre-treatment with NAC prevented t-PMB-induced 
inhibition of cell viability. On the other hand, treatment with t-PMB in the presence of 
ascorbate and TROLOX resulted in viability levels similar to that of WHCO1 cells treated 
with t-PMB alone, indicating that although these scavengers decrease ROS levels in t-PMB-
treated cells, they do not affect cell-viability. Since NAC, a cysteine-derivative with a free 
thiol group, restored cell-viability, but not ascorbate or TROLOX, we anticipated that NAC 
may be acting through a mechanism other than ROS scavenging. We proposed that NAC may 
in fact react with t-PMB to form a mixed disulfide product, thereby decreasing the 
concentrations of t-PMB within the WHCO1 cells. To test this hypothesis, a reaction 
between t-PMB and NAC was set up in THF at room temperature. The two compounds were 
in fact found to react to form a product, which was characterised by 
1
H Nuclear Magnetic 
Resonance spectroscopy (
1
H NMR) and found to be N-acetyl methoxybenzyl disulfide, a 
mixed disulfide product of t-PMB and NAC. It is therefore likely that this reaction may take 
place in the WHCO1 cells, thereby lowering the concentration of t-PMB, and preventing t-
PMB from inhibiting WHCO1 cell viability. Treating WHCO1 cells with the IC50 
concentration of 200 did not result in increased levels of ROS production, although pre-
treatment with NAC still restored cell viability. This result further supports the argument that 
NAC may not be restoring cell-viability in t-PMB- and 200-treated cells through its ROS 
scavenging property. A study by Kelkel et al. (2012) showed that when DAS4, a garlic-
derived OSC, was co-incubated with NAC, DAS4 was no longer able to induce β-tubulin 
polymerisation. It is highly likely that DAS4, like t-PMB, may form a mixed disulfide with 
NAC, thereby preventing the interaction between DAS4 and β-tubulin. In a study by Dirsch 
et al. (1998), it was shown that ajoene-induced apoptosis in HL-60 leukemia cells was 
blocked by NAC, but not by catalase. It may be that ajoene, like t-PMB, also forms a mixed 
disulfide product with NAC, thereby lowering the concentrations of ajoene within the cell. 
The results from our study indicate that although treating WHCO1 cells with t-PMB results 
in increased levels of ROS, ROS production does not appear to be important in the anti-




(2007) who observed that when DADS-treated T98G and U87MG glioblastoma cells were 
pre-treated with ascorbate, a decrease in apoptosis was observed. Our findings also contradict 
the findings by Kwon et al. (2002) who showed that pre-treatment with catalase prevented 
DADS-induced PARP cleavage in HL-60 leukaemia cells. It may therefore be that the OSC-
induced anti-cancer mechanism through ROS production may be cancer cell-line specific or 
analogue specific. 
Previous work in our laboratory has shown that DP, a fluorescent ajoene analogue, co-
localises to the endoplasmic reticulum (ER) in MDA-MB-321 breast cancer cells (Kaschula 
et al, unpublished data). Since thiolation appears to be important in the anti-cancer 
mechanism of OSC analogues, we propose that the OSC drug target may reside in the ER. An 
attractive target that we decided to investigate in this regard is Protein Disulfide Isomerase 
(PDI) whose active-site cysteine residues are involved in the formation of correctly paired 
disulfide bonds involved in protein folding (Lyles & Gilbert 1991). Because the active site 
cysteine residues of PDI are able to react with, and rearrange disulfide bonds within proteins, 
we hypothesised that the disulfide within OSC may also react with the active site cysteine 
residues of PDI, thereby preventing the interaction between PDI and its substrate proteins. 
For IHC, we selected the KYSE-180 oesophageal cancer cell-line as it expresses the highest 
levels of the PDI protein within a series of cancer cell-lines tested. All of the PDI in the 
KYSE-180 cells appeared to co-localise with DP, although DP also appeared localised to 
regions of the cell where PDI was not detected, suggesting that DP may have additional 
targets within the cell, like glutathione reductase (Krauth-Siegel et al. 1996) or β-tubulin 
(Hosono et al. 2005), which are proposed targets of garlic OSC.  
To determine whether OSC are able to inhibit PDI enzyme activity, a PDI enzyme assay was 
performed. DTNB, a known inhibitor of PDI (Jain et al. 2007; Mandel et al. 1993; Lara et al. 
2011; Santos et al. 2009), as well as synthetic garlic analogues; t-PMB, 200 and DP, 
inhibited PDI enzyme activity compared to the untreated control.  Furthermore, 200, whose 
leaving group has a pKa-value of 2.71, was shown to be more effective at inhibiting PDI’s 
enzymatic activity than t-PMB, whose leaving group has a pKa of 6.82, suggesting that the 
correlation we observed between pKa and IC50 may also be translated into the inhibition of 
PDI enzymatic activity. 
FACS analysis showed that WHCO1 cells treated with 200 or t-PMB showed a time-




phases of the cell-cycle. The G2/M cell-cycle arrest appeared earlier for 200-treated cells than 
t-PMB-treated cells. Although OSCs form garlic have been shown to induce a G2/M cell-
cycle arrest, this is the first time it has been observed for the thiosulfonate class of compound. 
Previous work in our laboratory has shown that when WHCO1 cells are treated with E/Z4l, 
ER stress is activated (Kaschula et al., unpublished). We hypothesise that should OSC inhibit 
PDI within cancer cells, it may lead to an accumulation of unfolded proteins and 
subsequently ER stress, and cell death. A study by Bourougaa et al. (2010) showed that ER 
stress promotes PERK-dependent induction of p53/47 homo-oligomerization, which 
subsequently induces G2/M cell-cycle arrest, but not G1 cell-cycle arrest (Bourougaa et al. 
2010), a cascade of events which may take place in WHCO1 cells treated with OSC. It would 
therefore be important for us to test this pathway in WHCO1 cells treated with OSC, to 
determine whether the ER stress leads to the observed G2/M cell-cycle arrest.  
To determine whether a degree of selectivity exists for cancer cells over non-cancer cells, 
Het1A, a non-cancer cell-line of oesophageal epithelia origin, was treated with t-PMB and 
200 and analysed using the MTT cell viability assay. The results showed that t-PMB 
displayed a 2.5-fold selectivity to WHCO1 cells over the Het1A cells, with 200 displaying a 
respective 10-fold selectivity. To investigate whether t-PMB and 200 are able to decrease 
cell viability in another cancer cell-line, the 48-hour IC50 of each compound was determined 
against the A375 human melanoma cell-line, and was found to be 2.27 μM for t-PMB and 
3.17 μM for 200, indicating that both compounds are more active against A375 cell 
proliferation than against WHCO1 cells. This result suggests that t-PMB and 200 display 
some selectivity for certain cancer types, similar to what has been observed for DADS, where 
the IC50 ranges from 22 μM for the human colon cancer cell-line, COLO205 (Yang et al. 
2009), to 35 μM for the human prostate cancer cell-line, PC-3 (Dong Xiao et al. 2005). 
Importantly, the 48-hour IC50’s of t-PMB and 200 against WHCO1 cells were found to be 
14.8 μM and 9.9 μM respectively, both falling into the in vitro clinical range of known 
oesophageal cancer chemotherapeutics; cisplatin (48-hour IC50 = 9.2 μM) and 5-fluorouracil 
(48-hour IC50 = 7.9 μM), on the same cell-line (Kaschula et al, 2012). Together, these results 
suggest that both compounds may have potential as cancer chemotherapeutics.  
To investigate the in vivo anti-cancer activity of 200, nude mice with an A375 xenograft were 
treated with 50 mg/kg 200 through intraperitoneal injection (IP) daily, which was found to be 
toxic as 4/ 9 mice in the group died. The dose was therefore decreased to 25 mg/kg 200 via IP 




healthy and gained weight. In addition, histopathalogic analysis showed no toxicity to the 
liver, kidney, adrenal gland, lymph node, heart or lung when analysed at the end of the 
experiment. Tumour size in the treatment group was significantly reduced for up to 18 days, 
although, when the tumour started growing more rapidly, the significance was lost. An in 
vivo study with 200 in nude mice with the WHCO1 xenograft was also performed. Here, the 
nude mice were initially treated with 20 mg/kg 200 via IP injection daily for the first 6 days, 
although after observing abdominal swelling in some mice, the dose was then decreased to 10 
mg/kg 200 via IP injection daily. Although an overall reduction in tumour size was observed 
in the treated mice, a significant reduction in tumour size was only observed at 7 days post-
treatment, likely due to the high concentration of 20 mg/kg 200 given within the first 6 days. 
It is evident that 200-treated nude mice with the A375 xenograft displayed a more significant 
reduction in tumour size compared to nude mice with the WHCO1 xenograft. The observed 
increase in in vivo anti-cancer activity of 200 in mice with the A375 xenograft over mice with 
the WHCO1 xenograft is not too surprising as the IC50 of 200 was 3-fold lower against the 
A375 cell-line (3.17 μM) compared to the WHCO1 cell-line (9.9 μM). Furthermore, nude 
mice with the A375 xenograft received 25 mg/kg 200 every second day, whereas mice with 
the WHCO1 xenograft received 10 mg/kg 200 daily. It is therefore possible that treating with 
a higher concentration of 200 every second day may be more effective than treating with a 
lower dose daily. This result is supported by previous findings where it was observed that 
mice with a human colon cancer xenograft (HCT-15) treated with 25 mg/kg DADS via IP 
injection three times a week, significantly reduced tumour size by 70 %, without adverse 
side-effects (Sundaram & Milner 1996b). Furthermore, mice with a human leukaemia (HL-
60) xenograft also showed a significant decrease in tumour size when treated with 42 mg/kg 
DADS via IP 3 times a week (Liao et al, 2007).  
Pharmacokinetic analysis on blood isolated from nude mice 1 hour post-treatment with 10 
mg/kg 200 showed that 200 was not detected, implying metabolic instability. The observed 
over-all decrease in WHCO1 tumour size in 200-treated mice may therefore have been 
because (1) 200 enters the blood stream and reaches the tumour site in under 1 hour following 
IP injection, or (2) that the tumour reduction was due to the effect of a metabolite of 200, or 
(3) that 200 may be altering tumour growth through another effect and is never reaching the 
tumour to act according to the mechanism we observe in vitro. Furthermore, although 200 
had higher in vitro anti-cancer activity compared to DADS (IC50 ≈ 50 μM), DADS appears to 




showed that nude mice with the HCT-15 human colon cancer xengraft treated with 1 mg 
DADS via IP injection thrice a week for 3 weeks, resulted in a 69 % reduction in tumour size, 
with no adverse side effects. The reduction in tumour size only within the early stages of 
tumorigenesis, and the fact that no compound was detected in the blood 1 hour after IP 
injection, suggests that 200 is not active enough in vivo or metabolically stable enough to be a 
suitable candidate for drug development in the future.  
The in vivo anti-cancer activity of t-PMB was also investigated in nude mice with the A375 
xenograft. Here, the nude mice were treated with 30 mg/kg t-PMB via daily IP injection. 
Although a significant reduction in tumour volume was observed up to 18 days of treatment, 
significance was lost when the tumour started to grow more rapidly, which was confirmed 
when no significant difference was observed between tumour weights in the t-PMB-treated 
and untreated groups at the end of the experiment. Furthermore, although the mice appeared 
healthy and gained weight over time, the mice experienced abdominal swelling, indicating 
that treating mice with 30 mg/kg t-PMB was too high. This result contradicts literature 
findings where it was observed that 80 ppm of the cauliflower-derived thiosulfonate, S-
methylmethane thiosulfonate (S-MMTS), significantly reduced colon cancers in mice and rat 
models without adverse side-effects (Reddy et al. 1999; Kawamori et al. 1995). Our findings 
indicate that t-PMB, although displaying excellent in vitro activity, may not be suitable as a 

















A small library of 15 garlic-related compounds were synthesised and assessed for in vitro 
anti-cancer activity. It was found that the stability of the leaving group plays a significant role 
in the WHCO1 anti-proliferative activity of disulfides, where compounds that don’t have 
leaving groups that can stabilise a negative charge have IC50’s greater than 200 µM. The 
strong anti-proliferative effects observed for the thiosulfonates is likely due to the 
electronegative effects of the oxygen atoms on the thiosulfonate, resulting in an 
electropositive sulfur which is more reactive towards an incoming cysteine nucleophile. The 
results in the structure-function study of disulfides and thiosulfonates supports the hypothesis 
that protein thiolation may be important in the anti-cancer mechanism of organosulfur 
compounds (OSC). 
The mechanistic study revealed that thiosulfonate and disulfide analogues, similar to garlic-
derived OSC, induce G2/M cell-cycle arrest and apoptosis. Although ROS is produced in the 
thiosulfonate series, but not the disulfide series, it does not appear to be implicated in the 
anti-proliferation cancer mechanism of the thiosulfonates. Furthermore, we found that NAC 
and t-PMB chemically react, rendering NAC an inappropriate ROS scavenger for OSC 
studies. 
For the first time, we have shown that OSC co-localise with, and inhibit the enzymatic 
activity of PDI, a protein involved in the correct pairing of disulfide bonds within proteins 
during tertiary folding. We hypothesise that OSC may inhibit PDI enzyme activity within 
cancer cells, leading to an accumulation of unfolded proteins and subsequent ER stress 
leading to cell death.  
In vivo anti-cancer studies showed that 200 is more effective at reducing tumour growth in 
mice with an A375 xenograft than in the WHCO1 xenograft, and furthermore that a higher 
dose (25 mg/kg) given every second day appears to be more effective that a lower dose given 
(10 mg/kg) daily. Pharmacokinetic data showed 200 to be metabolically unstable, suggesting 
that 200 may not be a good candidate for drug development. In vivo studies in nude mice with 




significantly within the first 18 days of treatment, the mice experienced abdominal swelling, 
suggesting that t-PMB too may not be a good candidate for further drug development.  
In summary, DADS analogues and thiosulfonate compounds, which each contain an activated 
disulfide functional group, appear to inhibit cancer cell viability, where the representative 
compounds, t-PMB and 200, appear to be selective towards cancer cells over their non-
cancer counterparts, inducing a G2/M cell-cycle arrest as well as apoptosis in WHCO1 cells; 
anti-cancer properties observed for garlic-derived OSC. Although ROS production did not 
appear to be important in the anti-cancer mechanism of t-PMB and 200, both compounds 
inhibited PDIs enzymatic activity, suggesting that PDI may be a prospective OSC target, and 
would be interesting to investigate in future studies. These findings, together with the in vivo 
results, support the idea that the regular consumption of garlic may inhibit tumour cell 
growth, but most like only within the early stages of tumorigenesis. Our results therefore 
refute the hypothesis that ROS production is important in the anti-cancer mechanism of OSC, 
but support the hypotheses that PDI may be a potential target for OSC within cancer cells, 


















Materials and methods 
 
8.1. Determining compound purity and stability 
8.1.1. Thin layer chromatography (TLC) 
All garlic-related organosulfur compounds used were synthesised at the Chemistry 
department of UCT in Prof. Roger Hunter’s Laboratory. An aliquot of each compound 
diluted in dimethyl sulfoxide (DMSO) (Sigma) was drawn up with a Hirschmann 
micropipette (Sigma) and then absorbed onto a TLC Silica gel 60 F254 aluminium plate 
(Merck). The plate was then placed into a developing tank with hexane and ethyl acetate 
(EtOAc), which was mixed in a ratio of either 10 % ethyl acetate (EtOAc):hexane for the 
DADS analogues  or 50 % EtOAc:hexane for the thiosulfonates. After the hexane-EtOAc 
moved up by at least 3 cm of the plate, the solvent front was marked, and the distance the 
compound had migrated was viewed under ultra-violet light at 254 nm. The compound’s 
relative purity was then gauged by viewing the number of “spots” on the sheet. 
8.1.2. Nuclear Magnetic Resonance (NMR) 
The purity of selected compounds giving only one spot on TLC was confirmed using Nuclear 
Magnetic Resonance Spectroscopy. 
1
H NMR spectra were recorded at 300 MHz in 
deuteriochloroform. Chemical shifts were recorded using residual chloroform (δ 7.26 in 
1
H 
NMR) as an internal standard. All chemical shifts are reported in parts per million (ppm) and 
all coupling constants quoted in hertz (Hz). The 
1
H chemical shifts of the compounds were 
compared to those previously reported and were found to be identical. (Stellenboom et al, 
2010). 
8.2. Toxicity studies 
8.2.1. Cell line used in assays 
The toxicity and IC50 studies were conducted using an epithelial oesophageal cancer cell-line, 
WHCO1 (Veale & Thornly, 1989). For the animal studies, both the WHCO1 oesophageal 
cancer and A375 human melanoma cell-lines were used (A-375 [A375] ATCC
®
 CRL-




WHCO1, A375, HeLa, KYSE-180, PC-3, SiHa and MDA-MB-231 cancer cell-lines. The 
HeLa cell-line was derived from cervical cancer cell-lines from Henrietta Lacks in 1951 
(Scherer & Syverton 1952). The KYSE-180 cancer cell-line was derived from a Japanese 
male with oesophageal squamous cell carcinoma. The PC-3 cancer cell-line was derived from 
a 62 year old Caucasian male with human metastatic prostate cancer of epithelial morphology 
(PC-3 [PC3] ATCC
®
 CRL-1435™).  The SiHa cancer cell-line is a grade 2 cervical squamous 
cell carcinoma derived from a 55 year old Asian female (SiHa [SiHa] ATCC®HTB-35™). 
Lastly, the MDA-MB-231 cancer cell-line is an epithelial breast cancer adenocarcinoma 
derived from a 51 year old Caucasian female (MDA-MB-231 [MDAMB231] ATCC
®
 HTB-
26™). As a non-cancer control cell-line, Het-1A cells were used, which is an oesophageal 
epithelial cell-line derived from a 25 year old black male, immortalised with the SV40 large 
T antigen (Het-1A [Het1A] ATCC® CRL-2692™). 
8.2.2. Cell culture media 
WHCO1 cells were cultured in Dulbecco’s modified Eagles medium (DMEM) (Gibco) (See 
appendix for preparation), supplemented with 10 % foetal calf serum (FCS) (HyClone) and 1 
% penicillin G/ streptomycinsulfate (PenStrep) (Biochrom) (See Appendix for preparation).  
8.2.3. Cell maintenance 
  8.2.3.1. Storage of cells 
Adherent cells were grown to an 80 % confluence in complete DMEM on a 100 mm dish. To 
collect cells, the media was removed and cells were washed with 5 ml phosphate buffer saline 
(PBS) (pH 7.5), where after the cells were incubated with 3 ml trypsin (37 °C, 5 % CO2, 91 
% humidity) (See appendix for preparation) for 2 minutes to detach cells from the dish. After 
transfer of the cells to a 12 ml tube, the trypsin was neutralised by the addiction of 4 ml 
complete DMEM  and centrifuged at 4000 rpm for 3 minutes (Hettich Zentrifuge). The 
supernatant was removed and cells were re-suspended in 5 ml DMEM containing 10 % FCS. 
Once the cells were re-suspended, 10 μl was removed to count the cells (see Section 8.2.4). 
The cells were pelleted by centrifugation at 4000 rpm (1541 ×g) and re-suspended in DMEM 
containing 20 % FCS and 10 % DMSO at a concentration of ~ 1×10
6
 cells/ml. Cells were 
stored in 1 ml aliquots in cryotubes at - 80 °C for 48 hours, then transferred to liquid nitrogen 
for long-term storage. 





When required, cells stored in liquid nitrogen were retrieved and thawed in a 37 °C water 
bath. The 1 ml cell suspension was added to a 12 ml Falcon tube containing 5 ml complete 
DMEM. The suspension was centrifuged at 4000 rpm (1541 ×g) for 3 minutes. The 
supernatant was removed, the cells were re-suspended in 5 ml complete DMEM and then 
transferred to a 100 mm dish containing 10 ml complete DMEM. The cells were incubated at 
37 °C, with a medium change after 24 hours. 
  8.2.3.3. Plating and splitting 
When the plates were 80 % confluent, the cells were split. For the splitting procedure, the 
medium was removed and cells were rinsed with 5 ml PBS (pH 7.5) (See Appendix for 
preparation) and incubated at 37 °C with 3 ml trypsin for 2 minutes to detach the cells. The 
detached cells were transferred to a 12 ml tube containing 4 ml complete DMEM. The 
suspended cells were centrifuged at 4000 rpm (1541 ×g) for 3 minutes. Thereafter, the 
supernatant was removed and the cells were re-suspended in 5 ml complete DMEM. The 
suspended cells were plated in a 100 mm dish containing 10 ml complete DMEM and 
incubated at 37 °C. Thereafter, the medium was changed every 2-3 days. 
8.2.4. Cell count 
To determine the number of cells, 10 μL re-suspended cells were stained with 10 μL Trypan 
blue (Molecular Probes®) of which 10 μl was pipetted into a Countess glass slide (Molecular 
Probes®) and cells were counted using the Countess cell counter (Molecular Probes®). To 
determine the volume of cells needed, the following formula was used: 
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8.3. Cell Morphology 
A change in cellular morphology may indicate cellular stress that may be induced by 
treatment with drug. For the analysis, 5 × 10
4
 cells were seeded per well into 6 well-plates 
and allowed to settle and attach for 24 hours at 37 °C. Thereafter, cells were treated with 
either 2 × 48-hour IC50 of t-PMB and 200, or 0.1 % DMSO as a solvent control. Images were 
then captured at t = 0, 24 and 48 hours at random regions on the plate using an Olympus 




8.4. Cell viability (MTT assay) 
8.4.1. Cell culturing 
The MTT assay quantifies cell proliferation and viability. It is based on the cleavage of 
yellow tetrazolium salt to purple formazan crystals by metabolically active cells. This 
reaction involves the pyrimidine nucleotide co-factors; nicotinamide adenine dinucleotide 
(NADH) and nicotinamide adenine dinucleotide phosphate (NADPH). The formazan crystals 
formed by metabolically active cells are solubilised and the resulting colour is quantified 
using a scanning multi-well spectrophotometer. The assay is therefore useful to determine the 
viability of the WHCO1 cells treated with the various organosulfur compounds (OSC) to test 
their effect on the viability of the cells. 
For the MTT assay, cells were seeded in 96-well plates, at 2500 cells per well suspended in 
90 μl complete DMEM. Cells were allowed to attach and recover for 24 hours, and thereafter 
treated with 10 μl compound at concentrations and times specified below. 
The thiosulfonates and disulfides, which were synthesised by Dr. Nashia Stellenboom in the 
Chemistry department, were stored at - 80 °C until use. 200 mM Stock solutions of each 
compound were prepared in high purity 99.9% DMSO, with the exception of t-benzyl which 
was dissolved in ethanol due to its insolubility in DMSO. The solutions were sonicated for 10 
minutes at 37 °C to ensure complete dissolution. Thereafter, the stock solutions were further 
diluted in DMSO (with the exception of t-benzyl, which was diluted in ethanol) to generate a 
range of concentrations at 2-fold dilutions i.e. 200, 100, 50, 25, 12.5, 6.25, 3.13, 1.56, 0.78 
and 0.39 mM in a 96-well plate. These solutions were further diluted 100-fold into complete 
DMEM. Thereafter, the cells were treated with 10 μl compound in DMEM to give a final 
compound concentration in the cells of 200, 100, 50, 25, 12.5, 6.25, 3.13, 1.56, 0.78 and 0.39 
μM. All experiments were performed in quadruplicate. The negative controls for these 
experiments were always cells treated with 0.1% DMSO in medium, and the background 
reading was media with MTT with solubilisation solution alone. 
To test for cell viability, the MTT reagent (Sigma
®
) (See Appendix for preparation) was used 
and prepared according to the protocol described by Roche, with the exception that 10 % SLS 
(Sodium lauryl sulphate) (See Appendix for preparation) was used instead of 10 % SDS 
(Sodium dodecyl sulphate). After the 24- or 48-hour treatment with each compound, the cells 




Thereafter, solubilisation reagent (10 % SLS) was added to a final concentration of 5% and 
further incubated at 37 °C for 24 hours. 
The relative viability of cells was determined spectrophotometrically using the Multiskan FC 
multi-well reader (Thermo Scientific) at 595 nm. The data for each compound was analysed 
using PRISM (GraphPad Software, Inc.) and fitted using a non-linear regression with a 
sigmoidal dose-response curve (variable slope). The proliferation-IC50 and 95 % confidence 
interval for each compound was obtained in triplicate experiments  
8.5. Cell proliferation assay (BrdU assay) 
To determine the anti-proliferative effects of t-PMB and 200, the BrdU assay was performed 
using the Cell Proliferation ELISA, BrdU (chemiluminescence) kit (Roche). For the assay, 
2500 WHCO1 cells were seeded in complete DMEM in black 96-well plates, with clear-
bottoms. Cells were allowed to attach and recover for 24 hours, and thereafter treated with 
either t-PMB or 200 at twice their respective 48-hour IC50’s. 
From their stock solutions, compound 200 and t-PMB was diluted in DMSO to 20 mM and 
30 mM respectively. The compounds were then further diluted 100-fold in media to 200 μM 
for compound 200 and 300 μM for t-PMB. WHCO1 cells were then treated at a final 
concentration of either 30 μM t-PMB or 20 μM 200 in 0.1 % DMSO in quadruplicate, and 
incubated (37 °C, 5 % CO2, 91 % humidity) for 20 hours. The solvent controls for these 
experiments were cells treated with 0.1 % DMSO in media or media alone.  
8.5.1. Treating cells with BrdU-labelling reagent and BrdU antibody 
Cells treated with compound for 48 hours were incubated at 37 °C with 10 μl BrdU labelling 
solution for 4 hours. Thereafter, the labelling reagent was removed and the cells were treated 
with 100 μl FixDenat (to fix and denature the DNA) for 30 minutes at room temperature. The 
FixDenat solution was removed through inverting and tapping the 96-well plate. The cells 
were then treated with 100 μl anti-BrdU-POD working solution for 90 minutes at room 
temperature. After removing the anti-BrdU-POD, the cells were washed thrice with 100 μl 
washing solution. Thereafter, the peroxidase (POD) substrate solution was added to the cells 
followed by incubation for 3 minutes at room temperature before measuring the 





8.6. Cell-cycle analysis by fluorescence activated cell sorting (FACS) analysis 
For the cell cycle analysis, cells were seeded into a 100 mm dish and allowed to settle for 24 
hours in an incubator at 37 °C. Cells were treated with either 2 × IC50 t-PMB (52 μM), 2 × 
IC50 200 (40 μM), 0.1 % DMSO in media alone or media alone for 0, 6, 12, or 24 hours. 
From their stock solutions, compound t-PMB and 200 were diluted in DMSO to 52 mM and 
40 mM respectively. The compounds were then further diluted 100-fold in media to 520 μM 
for compound t-PMB and 400 μM for 200. WHCO1 cells were then treated at a final 
concentration of either 52 μM t-PMB or 40 μM 200 in 0.1 % DMSO in triplicate and 
incubated at 37 °C with compound for 24 hours. The solvent controls for these experiments 
were cells treated with 0.1 % DMSO in media or media alone.  
Medium from each plate was removed and cells were rinsed with 5 ml PBS (pH 7.5). Both 
the media and PBS were retained. The washed cells were trypsinised by the addition of 3 ml 
trypsin, transferred to a 50 ml tube, and centrifuged at 3000 rpm (596 ×g) for 5 minutes at 
room temperature. The cells were then re-suspended in 2 ml PBS (pH 7.5), and counted, 
followed by treatment with ice-cold 70 % ethanol to give a total volume of 10 ml, and stored 
at -20 °C (this can be stored for up to 2 weeks). 
The cells were suspended in 8 ml 70 % ethanol, centrifuged at 1000 rpm (97 × g) for 5 
minutes at room temperature, and the supernatant was removed, with 1 ml remaining, which 
was transferred to a 1 ml eppendorf, spun in a bench top centrifuge for 1 minute and the 
remaining supernatant removed. The cells were washed twice with 1 ml PBS (pH 7.5) in a 
bench-top centrifuge for 1 minute. RNase A was diluted in PBS (pH 7.5) to a final 
concentration of 10 mg/ml, and added in a ratio of 100 μl RNase A per 1 × 10
6
 cells. The 
propidium iodide (PI) staining solution (See Appendix for preparation) was added at a 
volume 9 times that of the RNase A to yield a final concentration of 1 × 10
6
 cells/ml 20 
minutes prior to FACS analysis. The FACS analysis was performed in the FACSCalibur® 
flow cytometer.   
8.7. Histone-association DNA fragmentation assay 
To determine whether our compounds induce apoptosis, the histone association assay was 
performed using the Cell Death Detection ELISA
PLUS
 kit from Roche. The assay is based on 




directed against DNA and histones respectively. This allows the specific determination of 
mono- and oligonucleosomes in the cytoplasmic fraction of cell lysates. 
For the assay, WHCO1 cells were seeded in 96-well plates at 2500 cells per well, and were 
allowed to settle for 24 hours in an incubator at 37 °C.  
WHCO1 cells were treated with either t-PMB or 200 at two-fold, one-fold or ½-fold their 
respective 24-hour IC50 concentrations or 0.1 % DMSO alone for 24 hours. The 96-well plate 
was then centrifuged for 10 minutes at 997 rpm (200 ×g) at room temperature, and 50 µl of 
the supernatant was removed. The cells were treated with 200 µl lysis buffer for 30 minutes 
at room temperature. 
8.7.1. ELISA assay 
After the cells were lysed, 20 µl lysate was transferred to the streptavidin multi-plate and 
incubated with 80 µl immune-reagent per well. The multi-plate was covered with adhesive 
foil and incubated, while shaking (200 rpm), for 2 hours at room temperature. The lysate was 
removed by inverting and tapping the plate, and thereafter washed thrice with 250 µl 
incubation buffer per well. Each well was treated with 100 µl ABTS solution, and incubated 
by shaking at 200 rpm until colour development was sufficient for photometric analysis. To 
stop the reaction, 100 µl ABTS stop solution was added per well and measurements were 
taken at 405 nm against ABTS stop solution. 
8.8. ROS assay 
The accumulation of ROS, which is coupled with increased oxidative stress, has been 
implicated in the pathogenesis of many diseases, including cancer. For the detection of ROS, 
the cell-permeable fluorogenic probe 2’, 7’ –dichlorodihydroflouroscin diacetate (DCFH-
DA) was used, which diffuses into the cell and is deacetylated by cellular esterases to form 
the non-fluorescent 2’, 7’ –Dichlorodihydroflouroscin, which is rapidly oxidised to highly 
fluorescent 7’ –Dichlorodihydroflouroscin diacetate (DCF) by ROS. The fluorescence 
intensity is proportional to the ROS present in the cell cytosol. The relative florescence 
intensity of DCF is measured at an excitation wavelength of 480 nm and an emission 




For the assay, WHCO1 cells were seeded in five sterile white 96-well plates at 10 000 cells/ 
well in complete DMEM, and allowed to settle and recover for 24 hours in an incubator at 37 
°C.  
8.8.1 Treating with DCFH-DA and OSC 
After the cells were allowed to settle and recover, the media was removed, cells were rinsed 
twice with 1 × PBS (pH 7.5) and then re-suspended in Krebs’ Ringer Buffer (KRB) 
supplemented with 10 μM DCFH-DA (Sigma). The cells were then treated with either 200 or 
t-PMB at doses ranging from 2-fold, 1-fold or ½-fold of each compounds respective IC50, and 
control cells were treated with 0.1 % DMSO or media alone in quadruplicate. As a positive 
control, cells were treated with 5 μM doxorubicin. To account for background DCFH-DA 
and/or OSC fluorescence, wells with no cells were treated with DCFH-DA, OSC or DCFH-
DA and OSC in KRB, and these fluorescence values were subtracted from their 
corresponding wells with cells. One 96-well plate was used per fluorescence reading, with 
readings taken at 0, 1, 2, 3 and 6 hours post-treatment at an excitation of 480 nm and an 
emission of 530 nm using a Cary Eclipse fluorescence spectrophotometer (Varian).  
 8.8.2. ROS inhibition 
WHCO1 cells were seeded in a sterile white 96-well plate at 10 000 cells per well in DMEM, 
and allowed to settle and recover for 24 hours in an incubator at 37 °C. The medium was 
removed, cells were washed twice with 1 × PBS (pH 7.5) and then re-suspended in KRB. 
Cells were then treated with ROS inhibitors; 7.5 mM N-acetyl-L-cysteine (NAC) (Sigma), 50 
µM L-Ascorbic acid (ascorbate) (Sigma) or 12.5 µM 6-Hydroxy-2,5,7,8-tetramethylchroman-
2-carboxylic Acid (TROLOX) (Calbiochem®) and incubated at 37 °C for 30 minutes. 
Thereafter cells were treated with 10 µM DCFH-DA and incubated for an additional 30 
minutes. Finally, cells were treated with either t-PMB or 200 at their respective 24 hour IC50 
concentrations, and control cells were treated with either 0.1 % DMSO or media alone in 
quadruplicate. To account for background DCFH-DA and/or OSC fluorescence, wells with 
no cells were incubated with DCFH-DA, OSC or DCFH-DA and OSC in KRB, and the 
fluorescence values were subtracted from their corresponding wells with cells. Fluorescence 
readings were taken 3 hours post-treatment with OSC at an excitation of 480 nm and an 





8.8.3. NMR on NAC and t-PMB reaction product 
A solution of t-PMB (150 mg, 0.486 mmol) in THF (5 mL) was added to N-acetyl cysteine 
(40 mg, 0.243 mmol), dissolved in THF (0.5 mL) at room temperature under nitrogen. The 
reaction was allowed to proceed at room temperature (26 °C) overnight (16 hours). The 
mixture was then evaporated under reduced pressure and the residue purified by silica gel 
chromatography to afford the product (53.6 mg, 0.188 mmol) in a 78% yield.  
8.9. Tumour growth in nude mice 
 8.9.1. Preparing WHCO1 oesophageal and A375 melanoma cancer cell-lines 
The animal study was approved by the Animal Ethics Committee (AEC), protocol number: 
0.12/003). The WHCO1 oesophageal and A375 human melanoma cancer cells were seeded in 
a 100 mm dish in complete DMEM, and allowed to settle and recover for 24 hours. 
Thereafter, cells were rinsed with 1 × PBS (pH 7.5) and incubated at 37 °C with trypsin until 
the cells detached. The cells in trypsin were then transferred to a 12 ml tube, and the plate 
was washed with complete DMEM and then transferred to the 12 ml tube. Cells were then 
collected by centrifugation at 4000 rpm (1541 ×g). Thereafter, the trypsin was removed and 
the cells were re-suspended in complete DMEM. Each mouse was subcutaneously injected 
with 5 × 10
6
 WHCO1 oesophageal or A375 human melanoma cells in a volume of 100 μl on 
the right side of the lower back. Immediately following the inoculations, mice with the A375 
melanoma xenografts were treated with either t-PMB or 200, whereas mice with the WHCO1 
oesophageal cancer xenograft was treated with 200 three days after tumour inoculation. 
 8.9.2. Preparing OSC 
The t-PMB or 200 was prepared immediately before treating the mice each day. Briefly, t-
PMB or 200 was diluted in PEG (Sigma), vortexed and then sonicated for 10 minutes at 
37°C. Thereafter chondroitin was added to the solution at a final concentration of 2.5 %, and 
the solution was vortexed.  DMSO was then added to the solution to a final concentration of 
10 %, whereafter vortexing and sonication was repeated, and the solution sterilized through 
filtration. The nude mice were then treated by intraperitoneal (IP) injection of 100 µl t-PMB 
or 200 at a final concentration of 30 mg/kg or 25 mg/kg (50 mg/kg for the first 4 days) 
respectively in nude mice with the A375 xenograft. Nude mice with the WHCO1 xenograft 
were treated with 20 mg/kg 200 for the first 6 days, where after the dose was decreased to 10 




chondtroitin only. Treatment continued every day until the largest tumour size was almost 
200 mm (the animal ethics protocol does not allow a tumour width greater than 20 mm). 
 8.9.3. Pharmacokinetic data on 200 
Pharmacokinetic analysis, done at the Pharmacology department of UCT by Ms. Carmen de 
Kock, was performed on the blood samples from mice treated with 200 to determine its 
concentrations in the blood. For the analysis, mice with the WHCO1 xenograft from the 
treated group received 10 mg/kg 200, and whole blood was collected in heparin coated tubes 
1 hour after treatment. The blood samples of the 200-treated mice were stored for 2 months at 
- 80 °C before the analysis was performed.  
A calibration curve for 200 ranging from 15.6 – 1000 ng/ml was prepared in mouse plasma, 
and quality control (QC) samples were prepared at two concentrations namely 400 ng/ml 
(QC1) and 800 ng/ml (QC2). The standards for the calibration curve and the quality control 
samples were extracted in duplicate. For the extraction procedure of 200 from the blood of 
mice, 10 μl blood was mixed with 100 μl acetonitrile, vortexed for 1 minute and then 
sonicated for 1 minute. Thereafter, the sample was centrifuged at 5750 ×g for 5 minutes and 
80 μl of the supernatant was transferred to the mass spectrometer (MS) vials for Liquid 
Chromatography Mass Spectrometry (LC/MS/MS) which was performed on the API 200 
(AB Sciex) LC/MS/MS instrument. The (MS) conditions are depicted in Table 8.3 and 8.4.  
 
Table 8.3. Electro spray ionisation settings for mass spectrometry analysis of 200 samples. 
Nebuliser gas (Gas 1) (arbitrary unit) 50 
Turbo gas (Gas 2) (arbitrary unit) 60 
CUR (curtain gas) (arbitrary unit) 20 
CAD (collision gas) (arbitrary unit) 6 
TEM (Source Temperature) (°C) 450 
IS (Ion Spray Voltage) (V) 5500 
 
The analytical column used was Luna PFP 3 μm, 50 x 2.0 mm (Phenomenex). The mobile 
phase consisted of acetonitrile and 10 mM ammonium acetate which ran isocratically for 6 
minutes, with a flow rate of 300 μl/min. The calibration curves fits quadratic (weighted by 




lower limit of quantification  was set at 15.6 ng/ml. The system suitability test is done before 
the batch, a SYS sample (a mid-level extracted sample) is injected 6 times and the acceptance 
criteria is that the peak area of the samples should be below 5%. 
Table 8.4. Mass spectrometry settings for mass spectrometry analysis of 200 samples. 
Protonated molecular ion mass (m/z) [M+H]+ 185.9 
Product ion mass (m/z) Quantifier 111.1 
Product ion mass (m/z) Qualifier 144.1 
Dwell time (ms) 150 
Declustering potential (V) 26.0 
Entrance potential (V) 6.5 
Collision energy (eV) 35 
Collision cell exit potential (V) 6.0 
 
8.10. Protein Disulfide Isomerase (PDI) 
8.10.1. Detection of PDI in various cell-lines 
To determine the levels of PDI expressed in different cancer cell-lines, protein lysate was 
collected to detect PDI by western blot analysis, and quantified using densiometric analysis. 
The cancer cell-lines used to detect PDI levels were HeLa, KYSE-180, PC-3, SiHa, A375, 
MDA-MB-231 and WHCO1. All apparatus used for the western blot were purchased from 
Biorad®, unless otherwise stated. For the assay, cells were grown to 90 % confluence, 
thereafter the media was removed, and cells were rinsed twice with 1 × PBS. The cells were 
treated with 1 × RIPA buffer (Cell signalling) supplemented with 1 × protease inhibitor 
(Roche®), for 5 minutes. The lysed cells were freeze-thawed thrice at - 80 °C/37 °C, and 
sonicated for ~ 2 seconds. The lysate was centrifuged at 14 000 rpm for 15 minutes at 4 °C. 
Thereafter, the supernatant was retained, and the pellet discarded, and the relative protein 
concentration in each sample was quantified using the Pierce® BCA Protein Assay Kit 
according to the manufacturer’s instructions. 
After protein quantification, 60 μg protein was mixed with 1 × protein loading buffer (See 
Appendix for preparation) to a final volume of 40 μl, and heated at 95 °C for 10 minutes. 
Thereafter, the lysate was centrifuged on a bench top centrifuge for 1 minute. The samples 




preparation) and an 8 % separating gel (See Appendix for preparation), where the protein  
separation took place in running buffer (See Appendix for preparation). The initial voltage 
was set to 100 V until the dye front reached the separating gel, at which stage the voltage was 
increased to 200 V until the bromophenol blue was 0.5 cm from the bottom of the gel. 
Once the SDS-PAGE was completed, the proteins were transferred to a nitrocellulose 
membrane (BioTrace
™
) at 100 V for 1.5 hours in ice-cold transfer buffer (See Appendix for 
preparation). Once the protein was transferred to the nitrocellulose membrane, the membrane 
was incubated with Ponseau stain (See Appendix for preparation) for 5 minutes to stain the 
proteins on the membrane. Thereafter, the membrane was washed with water to remove 
excess ponseau and an image of the membrane was taken using the CanonScan 4400F 
scanner (Canon).  
After the transfer, the nitrocellulose membrane was blocked by gentle shaking in 5 % fat-free 
powder milk diluted in TBST (See Appendix for preparation) at room temperature for 1 hour. 
Thereafter, the membrane was treated with rabbit anti-PDI (Enzo®) (1:1000) antibody at 4 °C 
overnight. Once labelled with the primary antibody, the nitrocellulose membrane was washed 
thrice with TBST (See Appendix for preparation), with each wash lasting 10 minutes. The 
nitrocellulose membrane was then incubated with the goat-anti-rabbit (Biorad) secondary 
antibody for 1 hour at room temperature with gentle shaking. Once labelled with the 
secondary antibody, the nitrocellulose membrane was washed thrice with TBST, with each 
wash lasting 10 minutes. The membrane was treated with LumiGLO Reserve™ 
chemiluminescence substrate (KPL) for 30 seconds and the relative chemiluminescence was 
detected using the UVP Biospectrum™ 500 Imaging System.  
To measure GAPDH as a loading control, the nitrocellulose membrane was stripped by 
incubating with glycine (pH 2.5) alternate stripping buffer (See Appendix for preparation) for 
10 minutes at room temperature while shaking. Thereafter, 1 M Tris-acetate (pH 7.5) (See 
appendix for preparation) was added to the stripping buffer to neutralise the solution. 
Thereafter the protocol for detecting GAPDH on the nitrocellulose membrane is the same as 
for anti-PDI. 
The relative quantities of PDI from each cell-line were detected by normalising with GAPDH 
as a loading control, which was measured through densiometric analysis using the UVP 





  8.10.2.1. Cell culturing 
To investigate the localisation of PDI and DP, 50 000 KYSE-180 cells were seeded onto a 
glass coverslip in a 6 well-plate in complete DMEM. The cells were incubated at 37 °C and 
allowed to settle and recover for 24 hours. The cells were then treated with 9 μM DP (IC50) in 
0.1 % DMSO or 0.1 % DMSO in media alone for 24 hours. 
Once cells had settled and recovered, the coverslips were washed with pre-warmed 1 × PBS 
(pH 7.5). The cells were then fixed and permeabilised by adding ice-cold absolute methanol 
and incubating at - 20 °C for 5 minutes. Thereafter, the cells were fixed with 4 % 
paraformaldehyde in 1 × PBS (pH 7.5) for 5 minutes at room temperature. 
Once the cells were fixed, the coverslips were blocked using 1 % bovine serum albumin 
(BSA) (Sigma) supplemented with 0.1 % Triton X-100 (Sigma) in 1 × PBS (pH 7.5) for 1 
hour at room temperature. Thereafter, the cells were treated with the rabbit anti-PDI (1:50 in 
blocking solution) antibody. The coverslips were sealed in a humidified chamber and 
incubated at 4 °C overnight. Once labelled with primary antibody, the cells were washed 
thrice with 1 × PBS, 10 minutes per wash. Thereafter, the coverslips were mounted with 
MOWIOL® 4-88 (See Appendix for preparation) to a glass slide, and incubated at room 
temperature overnight to allow the MOWIOL® 4-88 to set. Fluorescence was detected using 
the Olympus IX81F-3 fluorescence microscope where DP was detected with the NU filter 
(blue) and PDI was detected with the NG filter (red). 
 8.10.3. PDI enzyme assay 
To determine whether OSC inhibit PDI enzyme activity; DTNB, a known PDI inhibitor, t-
PMB, 200 and DP were used in a PDI enzyme assay, which is based on the oxidative 
renaturation of reduced RNase A by PDI. The renatured RNase A activity was assessed by its 
ability to hydrolyse cytidine 2’,3’-cyclic monophosphate (cCMP), where the hydrolysed 
product can be detected spectrophotometrically at 296 nm. 
RNase A from bovine pancreas was denatured overnight in 6 M guanidine hydrochloride 
(Sigma®), 0.14 M DL-Dithiothreitol (DTT) (Sigma®) and 2 mM EDTA disodium salt 
(univAR®) (See Appendix for prepration) in 0.1 M Tris-acetate (pH 8.0) (See Appendix for 




guanidine hydrochloride and EDTA through centrifugal filtration (14 000 rpm) using a 3000 
molecular weight cut off VIVASPIN 500 (satorius stedim) filter unit. To confirm that PDIs 
isomerase activity on RNase A leads to the renaturation of reduced (denatured) RNase A, and 
the subsequent hydrolysis of cCMP, a cocktail mixture of Tris-acetate buffer (pH 8.0) with 
4.5 mM cCMP (Sigma®), 1 mM reduced L-glutathione (GSH) (Sigma®), 0.2 mM L-
glutathione oxidised disodium salt (GSSG) (Sigma®) and 1.4 μM bovine PDI (Sigma®) was 
initiated by the addition of the 8.4 μM reduced RNase A. The hydrolysis of cCMP, which 
results from the gain in RNase A activity, was recorded at 296 nm 35 minutes after the 
initiation of the reaction using the Cary Eclipse UV spectrophotometer. To confirm the 
inhibitory activity of DTNB, and assess whether t-PMB, 200 and DP display inhibitory 
activity against PDI, PDI was treated with 100 μM DTNB, 20 μM t-PMB, 20 μM 200 or 20 
μM DP 10 minutes prior to its addition to the reaction cocktail. Again, 8.4 μM reduced 
RNase A was added to initiate the reaction. As a background control, 8.4 μM denatured 
RNAse A was added to Tris-acetate buffer (pH 8.0), 4.5 mM cCMP, 1 mM GSH (Sigma®) 
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Appendix: Reagent Contents 
 
Acrylamide/bisacrylamide stock solution (30 %) (29:1): 
For the acrylamide/bisacrylamide stock solution, 29 g Acrylamine and 1 g bisacrylamide was diluted 
in 100 ml double distilled water and stored in the dark at 4 °C. 
Alternate stripping solution: 
1 M Glycine at pH 2.5. 
10 % Ammonium persulfate (APS): 
100 mg APS was dissolved in 1 ml double-distilled water, and stored at 4 °C. 
Coomassie staining solution: 
For the preprataion of coomassie staining solution, 0.5 g Coomassie BB was diluted in 200 ml 
methanol, 100 ml acetic acid and 400 ml double-distilled water. 
Destaining solution: 
Destaining solution included 100 ml acetic acid, 100 ml methanol and 800 ml double-distilled water 
and stored at room temperature. 
Dulbecco’s minimal eagle media (DMEM): 
The DMEM is made from DMEM Powder, catalogue number 12800-017, and is made according to 
the manufacturer’s instructions. 
0.5 M EDTA (pH 8.0): 
37.22 g Na2EDTA·2H2O was added to 140 ml double distilled water. The pH was adjusted to 8.0 with 
NaOH, where after double-distilled water was added to a final volume of 200 ml, and the solution 
autoclaved and stored at room temperature. 
MOWIOL® 4-88 mounting medium: 
75 g MOWIOL 4-88 ® (Calbiochem) mounting medium was diluted in 300 ml 1× PBS and stirred for 
16 hours at room temperature. Thereafter, 150 ml glycerol was added, and the solution was stirred for 
a further 16 hours at room temperature and centrifuged for 15 minutes at 4000 rpm in 50 ml Falcon 
tubes where after the pH of the solution was adjusted to 8. The supernatant was stored in aliquots at -
20 °C, supplemented with n-Propylgallate. 
5 % Non-fat blocking solution: 
2.5 mg non-fat milk powder was dissolved in 30 ml TBST, which was dissolved to a final volume of 
50 ml with double-distilled water. 
5 mg/ml 3-[4,5-dimethylthiazol]-2,5-diphenyltetrazolium bromide  (MTT): 
100 mg MTT (3-[4,5-dimethylthiazol]-2,5-diphenyltetrazolium bromide) (Sigma) was transferred to a 
50 ml conical tube. Under sterile conditions, 20 ml 1 × PBS (pH 7.5) was transferred to the 50 ml 
conical tube. The mixture was then vortexed and incubated in a water bath for 15 minutes. The 





For the preparation of the penicillin G/streptomycinsulfate solution, 604 mg (999620 IU) penicillin G 
and 1316 mg (1000160 IU) streptomycinsulfate was dissolved in 100 ml double-distilled water, and 
filter sterilised. 
10 × Phosphate Buffer Saline (PBS) (pH 7.5): 
For a 10 × PBS preparation NaCl (Merck), KCl (Merck), Na2HPO4 (Merck) and KH2PO4 (Merck) 
powders were diluted in double distilled water to 1.37 M , 27 mM, 43 mM and  14 mM  respectively, 
and finally calibrated to a final pH of 7.5. 
Ponseau staining soluntion: 
The Ponseau (usb®) staining solution was prepared by diluting Ponseau powder and acetic acid in 
double-distilled water to 0.2 % and 5 % respectively. 
Propidium iodide (PI) staining solution: 
Stocks of 100% Triton X-100, 1 M MgCl2, 1 M NaCl, 0.1 M PIPES and 1 mg/ml PI were diluted in 
20 ml double-distilled water to give a final concentration of 0.1 % Triton X-100, 2 mM MgCl2, 0.1 M 
NaCl, 10 mM PIPES and 0.01 mg/ml PI. The solution was stored in a 50 ml Falcon tube and covered 
with foil as it is sensitive to light. 
4 × Protein loading buffer: 
2.5 ml 1 M Tris at pH 6.8, 4 ml 20 % SDS, 0.2 ml 0.1 % bromophenol blue and 4 ml glycerol were 
mixed. 50 μl bromophenol blue (Merck) was added after the solution was diluted to a 1 × 
concentration. 
10 × Running buffer: 
Tris, glycine and SDS were diluted in double distilled water to a final concentration of 240 mM, 1.92 
M and 35 mM respectively. 
10 % Sodium dodecyl sulphate (SDS): 
10 g SDS was dissolved in 80 ml double-distilled water, then made to a final volume of 100 ml with 
double-distilled water. 
10 % Solubilisation reagent: Sodium Lauryl Sulfate (SLS): 
5 ml 1 M HCl was added to 50 g SLS (MERCK). The solution was further diluted with double 
distilled water to a final volume of 500 ml. 
4 % Stacking gel: 
0.63 ml 1 M Tris (Merck) at pH 6.8, 0.65 ml 30 % acrylamide/bisacrylamide (Sigma®) and 50 μl 10 
% SDS (Merck) was diluted in 3.65 ml double-distilled water. Immediately before adding to the gel 
tray, 25 μl 10 % ammonium persulfate (APS) (MERCK) and 5 μl TEMED (Sigma) was added to the 
solution. 
8 % Stacking gel: 
For the preparation of 8 % stacking gel, 3.75 ml 1 M Tris at pH 8.8, 2.7 ml 30 % 
acrylamide/bisacrylamide and 100 μl 10 % SDS was diluted in 3.39 ml double-distilled water. 
Immediately before adding to the gel tray, 50 μl 10 % ammonium persulfate (APS) and 5 μl TEMED 





To make up TBST, 50 ml 1 M tris-base, 20 ml 5 M NaCl and 250 μl Tween-20 was dissolved in 100 
ml double-distilled water, and stored at room temperature. 
10 × Transfer buffer: 
3.03 Tris and 14.5 glycine (Merck) were diluted to a final concentration of 24 mM and 193 mM 
respectively in 1 L double distilled water. 
Tris-buffered saline (TBS): 
3.03 g Tris (pH 7.5) and 9 g NaCl was added to final concentrations of 25 mM and 0.9 % (w/v) 
respectively in 1 L double-distilled water. 
1 M Tris pH 6.8 (per litre):  
Add 121 g Tris base to 800 ml double-distilled water, adjust the pH to 6.8, and add double distilled 
water to 1 L, then autoclave. 
1 M Tris pH 7.5 (per litre):  
Add 121 g Tris base to 800 ml double-distilled water, adjust the pH to 7.5, and add double distilled 
water to 1 L, then autoclave. 
1 M Tris pH 8.0 (per litre):  
Add 121 g Tris base to 800 ml double-distilled water, adjust the pH to 8.0, and add double distilled 
water to 1 L, then autoclave. 
1 M Tris pH 8.8 (per litre):  
Add 121 g Tris base to 800 ml double-distilled water, adjust the pH to 8.8, and add double distilled 
water to 1 L, then autoclave. 
Trypsin: 
Trypsin is made up by adding 0.5 g trypsin powder to 0.2 g EDTA powder, and making up to a total 
volume of 1 L with PBS buffer. The pH of the solution was adjusted to 7.4 and the solution was filter 
sterilised. 
 
 
 
 
 
 
